MISOPROSTOL USE IN POSTABORTION CARE

A Service Delivery Toolkit
MISOPROSTOL USE IN POSTABORTION CARE

A Service Delivery Toolkit
Acknowledgements

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agere Tadele</td>
<td>Ethiopia</td>
</tr>
<tr>
<td>Alyson Hyman</td>
<td>USA</td>
</tr>
<tr>
<td>Amina Dorayi</td>
<td>Nigeria</td>
</tr>
<tr>
<td>Ammanuel Gessessew</td>
<td>Ethiopia</td>
</tr>
<tr>
<td>Ann Leonard</td>
<td>USA</td>
</tr>
<tr>
<td>Asheber Getachew</td>
<td>Ethiopia</td>
</tr>
<tr>
<td>Aster Tsegaye</td>
<td>Ethiopia</td>
</tr>
<tr>
<td>Ayele Debebe</td>
<td>Ethiopia</td>
</tr>
<tr>
<td>Ayisha Diop</td>
<td>USA</td>
</tr>
<tr>
<td>Azza Karam</td>
<td>USA</td>
</tr>
<tr>
<td>Beverley Winikoff</td>
<td>USA</td>
</tr>
<tr>
<td>Bill Powell</td>
<td>USA</td>
</tr>
<tr>
<td>Binta Bello Danbata</td>
<td>Nigeria</td>
</tr>
<tr>
<td>Bridget Okeke</td>
<td>Nigeria</td>
</tr>
<tr>
<td>Cansas Mulligan</td>
<td>USA</td>
</tr>
<tr>
<td>Carol Odula-Obonyo</td>
<td>Kenya</td>
</tr>
<tr>
<td>Carol Tatua</td>
<td>Kenya</td>
</tr>
<tr>
<td>Claire Viadro</td>
<td>USA</td>
</tr>
<tr>
<td>Dagnachew Alemayoh</td>
<td>Ethiopia</td>
</tr>
<tr>
<td>Deborah Nucatola</td>
<td>USA</td>
</tr>
<tr>
<td>Dee Redwine</td>
<td>USA</td>
</tr>
<tr>
<td>Dereje Alemayoh</td>
<td>Ethiopia</td>
</tr>
<tr>
<td>Diana Greene Foster</td>
<td>USA</td>
</tr>
<tr>
<td>Dollina Odera</td>
<td>Ethiopia</td>
</tr>
<tr>
<td>Douglas Huber</td>
<td>USA</td>
</tr>
<tr>
<td>Ejike Oji</td>
<td>Nigeria</td>
</tr>
<tr>
<td>Ellen Israel</td>
<td>USA</td>
</tr>
<tr>
<td>Emmanuel Rwamushaija</td>
<td>Tanzania</td>
</tr>
<tr>
<td>Evelina Börjesson</td>
<td>USA</td>
</tr>
<tr>
<td>Felicia Ojemen</td>
<td>Nigeria</td>
</tr>
<tr>
<td>Florence Okoronkwo</td>
<td>Nigeria</td>
</tr>
<tr>
<td>Gezach Abraha</td>
<td>Ethiopia</td>
</tr>
<tr>
<td>Godwin O. Akaba</td>
<td>Nigeria</td>
</tr>
<tr>
<td>Graciela Salvador-Davila</td>
<td>USA</td>
</tr>
<tr>
<td>Hafsa Altaf</td>
<td>Pakistan</td>
</tr>
<tr>
<td>Hamleseb Merid</td>
<td>Ethiopia</td>
</tr>
<tr>
<td>Holly Blanchard</td>
<td>USA</td>
</tr>
</tbody>
</table>
Ricky Lu ............................................................ USA
Robyn Sneeringer .............................................. USA
Rodolfo Gomez Ponce de Leon ...................... Argentina
Sadiah Ahsan Pal ................................................. Pakistan
Safia Ahsan .......................................................... USA
Sarah Packer ........................................................ USA
Saumya Rama Rao .............................................. USA
Sharif Mohammed Ismail Hossain ............. Bangladesh
Sharon Arscott-Mills ........................................... USA
Shashu Araya ...................................................... Ethiopia
Sikiratu Kailani .................................................... Nigeria
Solomon Kumbu .................................................... Ethiopia
Sule Sa’adatu ........................................................ Nigeria
Susan Ouko ............................................................ Kenya
Susheela Engelbrecht .......................................... USA
Talemoh Dah ......................................................... Nigeria
Tarra K. McNally ................................................ USA
Tasneem Fatima .................................................. Pakistan
Tesanesh Belay ................................................... Ethiopia
Tesfaye Endrias ..................................................... Ethiopia
Tesfaye Haileselasse ............................................ Ethiopia
Thank-God Okosun ............................................. Nigeria
Traci Baird ............................................................. USA
Upeka de Silva .................................................... United Kingdom
Yolande Hyjazi ..................................................... Equatorial Guinea
Yonas Getachew .................................................. Ethiopia
This toolkit is promoted by the following organizations:

Population Council
Ipas Protecting women’s health
Advancing women’s reproductive rights

VSI Venture Strategies Innovations

PLANNED PARENTHOOD
MARIÉ STÖPES INTERNATIONAL
Venture Strategies
for Health and Development
UNFPA

IPPF
IntraHealth
EngenderHealth
for a better life
Pathfinder
a global leader in reproductive health

Bixby Center
for Population Health & Sustainability
Because Health Works.
EngenderHealth
for a better life
Pathfinder
a global leader in reproductive health

REPRODUCTIVE HEALTH SERVICES
QUALICARE
Jhpiego
EngenderHealth
for a better life
Pathfinder
a global leader in reproductive health

Kenya Obstetrics and Gynaecology Society
POSTABORTION CARE
PAC CONSORTIUM
IDEAS
Innovative Development Expertise
Advisory Services, Inc.
NCMNH
National Committee for Maternal & Neonatal Health

If your organization is interested in being added as a promoting agency to future printing and online versions of this toolkit, please contact misoforpac@ipas.org.
Overview

What is the service delivery toolkit?

Misoprostol for use in postabortal care: A service delivery toolkit provides information and tools to help district or national-level clinicians, facility managers or program managers to (1) initiate the use of misoprostol as a medical treatment for incomplete abortion or (2) integrate misoprostol into existing postabortal care (PAC) services that already use manual vacuum aspiration (MVA). The toolkit aims to facilitate the ability of all types of health facilities (such as hospitals, health centers, clinics and maternity homes) to offer misoprostol for treatment of incomplete abortion so as to increase women’s access to PAC services. The toolkit can be adapted at the country level. Users should determine the level of clinician who can deliver misoprostol for treatment of incomplete abortion at the local level, based on clinicians’ ability to perform core competencies.1

Who should use this toolkit?

This toolkit is meant for three audiences: program managers at the national/district levels, facility managers and clinicians. Note: Providing misoprostol for treatment of incomplete abortion is a simple procedure. This toolkit is not intended to make these services seem complicated but, rather, to support a range of professionals for both programmatic and clinical implementation. For minimum service delivery requirements, please see Tool 3A: Minimum requirements for treatment of incomplete abortion with misoprostol.

Not all modules or tools will be useful for all readers. Figure 1 suggests the modules that may be most relevant to each target audience. However, depending on your role, you may find tools or information from other modules helpful as well.

Figure 1:

| Program managers at the national/district level |
| Module 1: Introduction |
| Module 2: Planning for service delivery |
| Module 6: Ensuring high quality services |

| Facility managers |
| Module 1: Introduction |
| Module 2: Planning for service delivery |
| Module 3: Assessing your facility |
| Module 4: Creating community linkages |
| Module 6: Ensuring high quality services |

| Clinicians |
| Module 1: Introduction |
| Module 4: Creating community linkages |
| Module 5: Delivering clinical services |
| Module 6: Ensuring high quality services |

---

1. For more information, please consult Ipas and Gynuity Health Projects’ forthcoming training manual on misoprostol for incomplete abortion at www.ipas.org or www.gynuity.org
How can the toolkit be used?

Users may use the modules in the toolkit in two ways, either by following the modules in sequential order or by identifying the modules and tools that are most relevant and pulling these sections out of the binder. The tools should be seen as templates you can adapt to local needs and conditions.

Each tool is numbered (for example, 2G) and includes the tool icon 📚. Instructions on how to use the tools are at the beginning of each tool in *italics*. The accompanying CD makes all the tools available for adaptation and use. In addition, each module has a section that contains additional resources for related information. Throughout the toolkit, we highlight special considerations for populations with specific health needs, such as women in crisis or emergency situations, youth, women living with HIV/AIDS, and commercial sex workers.

The toolkit is based on the most recent evidence-based guidelines. Specifically, three key resources informed the development of the toolkit’s content, materials, and information on misoprostol for use in postabortion care. The resources include:

- *Postabortion care training materials and clinical guidelines.* (Venture Strategies Innovations 2009).

For updated clinical information and guidance on misoprostol for use in postabortion care, refer to www.gynuity.org, www.ipas.org and www.misoprostol.org. Refer to www.vsinnovations.org for additional information on global misoprostol programs. If you have questions regarding the content of this toolkit or require technical assistance, please contact misoforpac@ipas.org or info@vsinnovations.org.

The full toolkit is available online at http://www.ipas.org/ma/mpac-toolkit.
**TABLE OF CONTENTS**

**Module 1. Introduction** ................................................................. 1  
*Target audiences: Clinicians, facility managers and program managers at the national/district levels*

1.1 What is incomplete abortion? ................................................... 1

1.2 How can incomplete abortion be treated? .............................. 2

1.3 What are postabortion care (PAC) services? ........................... 3

1.4 Why use misoprostol in the provision of postabortion care? ..... 3

**Module 2. Planning for service delivery** ........................................... 5  
*Target audiences: Facility managers and program managers at the national/district levels*

2.1 Introduction .................................................................................. 5

2.2 Standards, guidelines and protocols .......................................... 9

2.3 Step-by-step planning ................................................................. 10

2.4 Ensuring sustainable supply of misoprostol .............................. 15

2.5 Additional resources ................................................................... 19

**Module 3. Assessing your facility** .................................................... 21  
*Target audience: Facility managers*

3.1 Introduction .................................................................................. 21

3.2 Models for integrating misoprostol into postabortion care services ............................................... 22

3.3 Using the results of the facility assessment tool ....................... 35

3.4 Additional resources ................................................................... 35
Module 4. Creating community linkages ...............................................................37
Target audience: Clinicians and facility managers

4.1 Introduction ...........................................................................................................37

4.2 Partnering to reach communities ........................................................................38
   Tool 4A. Quick community assessment guide .......................................................39

4.3 Strategies for working with communities .........................................................41
   Tool 4B. Potential audiences and topics for information, education and
   communication on misoprostol use in postabortion care .................................43

4.4 Additional resources .........................................................................................45

Module 5. Delivering clinical services ....................................................................47
Target audience: Clinicians

5.1 Introduction ...........................................................................................................47

5.2 Misoprostol: what it is and how it works ..........................................................47

5.3 Regimens and efficacy of misoprostol treatment for incomplete abortion ......47

5.4 Misoprostol for the treatment of missed abortion and anembryonic
   gestation ..................................................................................................................48
   Tool 5A. Misoprostol for treatment of incomplete abortion: Basic clinical
   protocol ....................................................................................................................49
   Tool 5B. Clinical flow chart .................................................................................55
   Tool 5C. Service delivery diagram ......................................................................57
   Tool 5D. Patient chart .........................................................................................59
   Tool 5E. Indications and regimens for misoprostol use ......................................65

5.5 Preparing women for what to expect ............................................................67
   Tool 5F. Brochures for women ............................................................................69
   Tool 5G. Managing expected effects, side effects and complications ..............73

5.6 Contraceptive services .....................................................................................75
   Tool 5H. Contraceptive pocket guide .................................................................77

5.7 Follow-up ............................................................................................................79

5.8 Referrals .............................................................................................................79
   Tool 5I. Referral form ..........................................................................................81

5.9 Learning from adverse events .........................................................................83
   Tool 5J. Serious adverse event form .................................................................85

5.10 Additional resources .......................................................................................89
Module 6. Ensuring high quality services ................................................................. 91
Target audiences: Clinicians, facility managers and program managers at the national/district levels

6.1 Introduction ........................................................................................................... 91
6.2 Monitoring to assess and improve quality of services ....................................... 91
6.3 Six monitoring areas of misoprostol use in PAC services .................................. 91
6.4 Developing a monitoring plan to ensure high quality of services ..................... 92
   Tool 6A. Indicators by facility level ........................................................................ 95
6.5 Gathering information for monitoring ............................................................... 97
   Tool 6B. Service delivery logbook ....................................................................... 99
   Tool 6C. Monthly service report ........................................................................... 101
   Tool 6D. Supervisory and performance quality improvement checklist ............. 103
   Tool 6E. Patient satisfaction rapid assessment .................................................... 107
6.6 Compiling and synthesizing monitoring data .................................................... 109
6.7 Developing a workplan for continuous quality improvement ......................... 109
6.8 Additional resources ............................................................................................ 111

References by Module ............................................................................................... 113

Annex 1: Clinical assessment reference guide: Overview of misoprostol for
the management of incomplete abortion ................................................................. 119

Annex 2: Selected publication abstracts on misoprostol use in
postabortion care
(Only available on the toolkit CD or online at http://www.ipas.org/ma/mpactoolkit)

Annex 3 - Tool 2D: Estimating misoprostol supply needs spreadsheet
(Only available on toolkit CD or online at http://www.ipas.org/ma/mpactoolkit)
List of acronyms

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACOG</td>
<td>American College of Obstetricians and Gynecologists</td>
</tr>
<tr>
<td>AE</td>
<td>Adverse event</td>
</tr>
<tr>
<td>AIDS</td>
<td>Acquired immunodeficiency syndrome</td>
</tr>
<tr>
<td>EmOC</td>
<td>Emergency obstetric care</td>
</tr>
<tr>
<td>FEFO</td>
<td>First-to-expire, first-out</td>
</tr>
<tr>
<td>FIGO</td>
<td>International Federation of Gynecology and Obstetrics</td>
</tr>
<tr>
<td>HIV</td>
<td>Human immunodeficiency virus</td>
</tr>
<tr>
<td>HTSP</td>
<td>Healthy timing and spacing of pregnancy</td>
</tr>
<tr>
<td>IUD</td>
<td>Intrauterine device</td>
</tr>
<tr>
<td>IUFD</td>
<td>Intrauterine fetal death</td>
</tr>
<tr>
<td>LMP</td>
<td>Last menstrual period</td>
</tr>
<tr>
<td>M&amp;E</td>
<td>Monitoring and evaluation</td>
</tr>
<tr>
<td>MIS</td>
<td>Management information system</td>
</tr>
<tr>
<td>MVA</td>
<td>Manual vacuum aspiration</td>
</tr>
<tr>
<td>NGO</td>
<td>Nongovernmental organization</td>
</tr>
<tr>
<td>PAC</td>
<td>Postabortion care</td>
</tr>
<tr>
<td>POC</td>
<td>Products of conception</td>
</tr>
<tr>
<td>PPH</td>
<td>Postpartum hemorrhage</td>
</tr>
<tr>
<td>RH</td>
<td>Reproductive health</td>
</tr>
<tr>
<td>SAE</td>
<td>Serious adverse event</td>
</tr>
<tr>
<td>STI</td>
<td>Sexually transmitted infection</td>
</tr>
<tr>
<td>VA</td>
<td>Vacuum aspiration</td>
</tr>
<tr>
<td>VCAT</td>
<td>Values clarification and attitude transformation</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
</tbody>
</table>
1.1 What is incomplete abortion?

Incomplete abortion occurs when there are retained products of conception (POC) after induced abortion (whether by unsafe or safe methods) or after spontaneous abortion, also known as miscarriage.

**Typical presenting symptoms of incomplete abortion are:**

- vaginal bleeding
- dilated cervix
- uterus smaller than indicated by date of last menstrual period

**Symptoms that are sometimes present are:**

- cramping or lower abdominal pain
- partial expulsion of products of conception

Incomplete abortion is often closely related to unsafe abortion (Gynuity Health Projects 2009). The World Health Organization (WHO) defines unsafe abortion as termination of an unintended pregnancy either by individuals lacking the necessary clinical skills or in an environment that does not conform to minimum medical standards, or both (WHO 1993). The WHO estimates that 21.6 million unsafe abortions take place each year, nearly all of which occur in developing countries (WHO 2011a). Unsafe abortions result in the deaths of an estimated 47,000 women annually, almost all preventable (WHO 2011a), and many more women suffer injuries and long-term health problems. Adolescent and young women below the age of 24 are disproportionately affected by unsafe abortion, accounting for 46 percent of deaths from unsafe abortion in the developing world (WHO 2007). The magnitude of unsafe abortion varies by geographic region and, within regions, by country.

It is important to know your country’s abortion laws and to be aware of the prevalence of unsafe abortion within your country. However, because postabortion care (PAC) does not fall under the same legal restraints as abortion provision, it can be provided even in settings where abortion is illegal.
1.2 How can incomplete abortion be treated?

The WHO has stated that the prompt treatment of incomplete abortion is an essential element of obstetric care (WHO 1991). Treatment of uncomplicated incomplete abortion can be provided at the primary care level (Gynuity Health Projects 2009).

Active management of incomplete abortion, using either vacuum aspiration or medical methods, is highly effective in treating incomplete abortion. Misoprostol, the most common and thoroughly studied medical method for treatment of incomplete abortion, is a newer option to expand PAC services into places where MVA may not be available. Misoprostol provides a highly effective, non-invasive treatment for incomplete abortion, enabling women to receive appropriate and effective postabortion care from non-surgically trained, mid-level providers (Blum et al. 2007). Whether MVA is available or not, misoprostol is a highly feasible option that can be used as a stand-alone first-line treatment for incomplete abortion. Because misoprostol and MVA are both appropriate methods for postabortion care, women ideally would have a choice between the two methods.

The WHO added misoprostol for incomplete and missed abortion to its Model List of Essential Medicines in 2009, based on the drug’s proven effectiveness and safety. The WHO list guides the development of national and institutional medicine lists, with the aim of focusing resources on medicines that help prevent and solve the most critical health problems. The list also shapes humanitarian emergency medical preparedness, guiding organizations that supply medicines for developing countries and those in crisis.

MISOPROSTOL ENDORSEMENTS

Misoprostol is included in the WHO Model List of Essential Medicines for incomplete abortion, as well as in the WHO Priority Medicines for Mothers and Children (WHO 2011b, WHO 2011c). In addition, it is recommended for use in postabortion care by the International Federation of Gynecology and Obstetrics (FIGO), the American College of Obstetricians and Gynecologists (ACOG), the Latin American Federation of Obstetrics and Gynaecology (FLASOG), the International Confederation of Midwives (ICM), and other international organizations and associations.

Another option for treating incomplete abortion is expectant management (allowing for spontaneous evacuation of the uterus). Although in some cases clinicians prefer not to use expectant management because of the lower rate of efficacy and unpredictable time

MANUAL VACUUM ASPIRATION (MVA)

Vacuum aspiration (VA) is a method by which the contents of the uterus are evacuated through a plastic or metal cannula that is attached to a vacuum source. Manual vacuum aspiration (MVA) uses a hand-held, portable aspirator. MVA is often used in PAC treatment for uterine evacuation (Herrick et al. 2004).
interval for expulsion (Clark et al. 2007), a woman should be given this option if she is clinically stable. Expectant management requires careful follow-up, however, to assess whether expulsion has occurred or to ascertain whether the woman needs additional treatment.

1.3 What are postabortion care (PAC) services?

Postabortion care consists of a series of interventions designed to manage a woman presenting after spontaneous or induced abortion (with or without complications). PAC is an important component of comprehensive reproductive health services because it saves women’s lives and reduces morbidity.

In 1993, leading reproductive health organizations and donor agencies formed the PAC Consortium (www.pac-consortium.org), in part to promote PAC as an effective strategy to address the global problem of incomplete abortion. The model for postabortion care supported by the PAC Consortium consists of five elements (Winkler et al. 2000):

- **Treatment** of incomplete and unsafe abortion and abortion-related complications that are potentially life-threatening;
- **Counseling** to identify and respond to women’s emotional and physical health needs and other concerns;
- **Contraceptive services and information** to help women prevent an unwanted pregnancy or practice birth spacing;
- **Reproductive and other health services** that are preferably provided on site or via referrals to other accessible facilities in clinicians’ networks;
- **Community and service-provider partnerships** to prevent unwanted pregnancies and unsafe abortion, mobilize resources to help women receive appropriate and timely care for complications from unsafe abortion, and ensure that health services reflect and meet community expectations and needs.

1.4 Why use misoprostol in the provision of postabortion care?

Misoprostol has been used safely for incomplete abortion in many different countries and has not been associated with any long-term effects on women’s health (Gynuity Health Projects 2009). Moreover, **misoprostol treatment has very minimal service delivery requirements and can be provided almost anywhere** (see Tool 3A: Minimum requirements for treatment of incomplete abortion with
misoprostol). There is an increasing body of evidence on the use of misoprostol to treat incomplete abortion:

- The average efficacy rates of misoprostol for postabortion care reported in the literature are 91-99 percent, depending on the regimen used and the study.

- Misoprostol is becoming increasingly recognized as a low-cost and easy-to-use means of uterine evacuation (Blum et al. 2007).

- Misoprostol is a simple technology that is easy to store (no refrigeration required and a long shelf life) and use in a range of settings, by a range of clinicians. Misoprostol for postabortion care can stand alone where MVA is not feasible, or complement MVA where there are existing PAC services.

- Misoprostol for the treatment of incomplete abortion has been clinically studied in settings as diverse as the United States, the United Kingdom, and in low-resource countries such as Burkina Faso, Egypt, Ghana, Mozambique and Tanzania (Bique et al. 2007, Dabash et al. 2010, Dao et al. 2007, Shwekerela et al. 2007, Taylor et al. 2011).

In studies reviewing acceptability, more than 90 percent of women have reported being satisfied or very satisfied with misoprostol for their postabortion treatment (Dao et al. 2007, Gynuity Health Projects 2009, Ngoc et al. 2005, Shwekerela et al. 2007, Weeks et al. 2005). A feasibility study in Nigeria showed high acceptability to women among a largely Muslim population in the north. The same study showed that participating clinicians (including doctors, midwives and nurses) also reported a high degree of satisfaction (Ipas Nigeria and SOGON 2011a, Ipas Nigeria and SOGON 2011b).

- Data from several studies show that, in many settings, reorganizing services by reclassifying PAC treatment as an outpatient care procedure substantially reduces the resources used for PAC, along with the cost and average length of women’s stay in health facilities (Billings and Benson 2005).

- Misoprostol can substantially reduce service costs, allowing women to seek treatment for incomplete abortion at the primary care level and thus reducing the caseload at tertiary care facilities (FLASOG 2007).

3. Abstracts from selected published studies are available at: http://www.ipas.org/ma/mpactoolkit/

2.1 Introduction

When planning to introduce misoprostol for postabortion care (PAC) services at the facility level, it is often helpful, although not required, to do some broader thinking about service delivery needs, the postabortion care that is currently available (if any), and the policies that will guide service implementation. (For a list of essential service delivery requirements, see Tool 3A: Minimum requirements for treatment of incomplete abortion with misoprostol.) In addition to laying the groundwork for new or expanded PAC services, this deliberative process should also establish or increase support for the use of misoprostol for postabortion care. Without wider institutional support, it will be hard to develop and sustain a program.

Module 2 provides you with guidance and tools to conduct an environmental assessment, review current policies and services, and estimate misoprostol supply needs. Where you work, and the planned scope of the misoprostol for postabortion care program, will determine the scope of the assessment and policy/service review. Your estimate of misoprostol supply needs will be based on your caseload and the various uses you plan for misoprostol.
Tool 2A.  
**Environmental assessment guide**

*Use this guide to help deepen your understanding of the environment in which you work, to better develop and implement misoprostol for postabortion care services. The environmental assessment may be as simple as convening a meeting of knowledgeable people to discuss the current situation and perceived needs, or reviewing data to understand the demand for postabortion care services in your setting. As you conduct the assessment, make sure to consider the needs of special populations such as women in crisis/emergency situations, youth, refugees, women living with HIV/AIDS, commercial sex workers, women facing sexual violence, and people impacted by other health conditions such as infectious diseases.*

**Public health context**

- Understand the size and geographic distribution of the population.
- Note the maternal mortality rate (at the national, regional or local levels).
- Note the proportion of maternal mortality attributable to unsafe abortion.
- Note the extent of maternal morbidity attributable to complications of unsafe abortion.
- Count the number of women treated for abortion complications monthly and/or annually in the catchment area of the hospital, district, or other location.
- Review the types of maternal complications most often seen in health-care facilities in the catchment area.
- Note the unmet need for contraception.

**Legal and regulatory context**

- Review existing laws and policies and their effects on the provision of abortion care (both treatment of abortion complications and legal abortion). Laws that are considered “restrictive” sometimes permit legal safe abortions in cases of rape and for other compelling reasons. Pay attention to any regulations that affect care for adolescents or unmarried women.
- Determine the types of clinicians who can currently treat incomplete abortion.
- Partner with a nongovernmental organization or other agency to review the status of misoprostol, including its registration and approved indications, inclusion on the national essential medicines list, ministry of health decisions about its use, and current evidence-based use (per label or off-label).

**Service delivery context**

- Note the availability of PAC services, including facilities that provide uterine evacuation with MVA and/or misoprostol. Note the facilities’ locations, their distribution relative to the number of women of reproductive age, and their staffing levels and hours.
- Review the ways in which women typically reach the health facilities.

---

Assess the adequacy of referral and transportation systems between facilities for treatment of abortion complications. Consider patient assessment, stabilization and referral to higher-acuity treatment when necessary.

Assess the training, if any, currently offered to health personnel on treating incomplete abortion and abortion complications.

Assess the availability of contraceptive services to women after an incomplete abortion, including whether the services are in the same space and facility as PAC services, or obtainable by referral.

Assess current contraception provision practices as part of postabortion care, and prevailing contraceptive acceptance rates of women treated at PAC facilities.
2.2 Standards, guidelines and protocols

It is important to review prevailing standards, guidelines and protocols to ensure that they facilitate access to care and that they encompass the use of misoprostol. If developing or updating national standards and guidelines is beyond the scope of your project, consider documenting the results of the use of misoprostol for postabortion care in just one facility or geographic area. You can then use the results to encourage a broader review and updating of national documents and drug usage policies.

National standards are very different from local or institutional protocols. In general, national standards are not reviewed regularly once they are approved. Thus, national standards should be as broad and non-specific as possible, so that local institutions can freely implement up-to-date clinical protocols as science evolves. For example, where a national standard might approve misoprostol for postabortion care, it would be left to the local or institutional protocol to lay out the specific regimens, contraindications, eligibility and so forth.

**Issues to consider when developing or reviewing standards, guidelines and protocols:**

- **Do not overmedicalize.** There is a strong tendency to require more than is necessary, such as specialized equipment, laboratory testing, or proof of a woman’s age, or to attempt to address extremely rare procedural complications. Misoprostol for use in postabortion care can be provided by primary care providers in remote areas; complicated equipment, testing, and procedures are not necessary for high quality care.

- **Include only evidence-based practices.** Do not describe practices that “seem like a good idea” or “have always been done that way” if they are not backed up by evidence.

- **Provide an appropriate level of detail** about service delivery, but allow for modification. Make sure that specific clinical protocols, such as the timing of repeat doses of misoprostol, are not codified in documents that are hard to update if the evidence base changes. Ensure that documents reflect the concerns of the primary care and community levels of the health-care system and the full range of health-care delivery settings, such as mobile units and private clinicians’ offices.

- **Do not add restrictions that are not required by law.** This includes barriers such as special clinician or site certifications or permitting only physicians to provide services.

- **Include public, private, and nongovernmental organization (NGO) sectors.** Unpublished experience has shown that provision of care through integration of the public and private sectors...
and NGOs eventually results in improved access, lower costs and higher quality services. Be sure that standards are the same for all three sectors.

- **Incorporate the elements of woman-centered care.** Woman-centered care is a comprehensive approach to meeting each woman’s medical and psychosocial needs, independent of age or marital status, at the time of service. Its core components include providing respectful, confidential services; involving women in their treatment; offering as many choices as possible; and ensuring that women’s rights to high quality care are honored.

### 2.3 Step-by-step planning

Whether planning for the introduction of new services with misoprostol or integrating misoprostol for postabortion care into existing PAC services, planning should be a careful and thoughtful process. The planning process outlined in the checklist below can guide you in understanding the needs of your community and patients, and help you design appropriate and feasible services to meet those needs.

Different people will have different ideas about how to improve services or create a new program. It is therefore important during the planning phase to elicit all relevant perspectives and ideas — especially from key leaders whose support is important to the program’s success and from the people your program will serve, including adolescents and other special populations.

Planning for changes in service delivery involves six key steps: identifying priorities, setting objectives, developing a workplan, training staff at all levels, planning for high quality, and planning for sustainability (Tool 2B: Checklist for planning for change in service delivery). The checklist will help you make sure that you are considering all the various elements that are essential in developing service delivery with misoprostol. As planners work through the checklist, they should take the following considerations into account:

1. **Identify priorities**

   Identify priorities for your community or patient population. Once you have a list of priorities, rank them based on urgency, impact and feasibility. In a rural area, for instance, the identified need might be to improve women’s access to postabortion services because the nearest existing clinician may be two hours away by vehicle.

2. **Set specific objectives**

Objectives should reflect the needs of women and the community. It is also important that objectives be achievable within the given time frame and with available resources. These objectives should help define your next steps for introducing or integrating misoprostol into postabortion care services.

3. **Develop a workplan**

Think through the steps that must be taken to accomplish each objective. Assign responsibility for each activity and develop a timeline for completion. Think about the “who, what, when, how and where” of each step. You will also need to develop a budget for your workplan and plan funding for your activities and services.

4. **Train staff at all levels**

All site training should be conducted with your staff, including values clarification exercises that will help reduce stigma and discrimination at the facility level. In addition, all staff should have a general understanding of how postabortion care services are provided to women. Finally, clinicians should receive specific training on the provision of PAC and misoprostol use in PAC.

5. **Plan for high quality**

You should identify ways to monitor the program and ensure high quality (see Module 6: Ensuring High Quality Services). In a facility-based program, involve the staff and patients in defining indicators of high quality service.

6. **Plan for sustainability**

To guarantee the effectiveness of services, it is critical to plan changes in such a way that they will endure over time. Different programs will require different actions to achieve sustainability, but certain elements are universally important:

- Obtaining the support of key decisionmakers
- Updating service standards
- Providing confidential and respectful care to all women
- Integrating postabortion care services with other reproductive health services
- Ensuring that funding mechanisms are in place
- Ensuring that supply, management and training systems function well
› Maintaining required equipment and the physical space where services are provided
› Maintaining supplies of consumables
› Monitoring services
Tool 2B.
Checklist for planning for change in service delivery

Whether you are planning to initiate new or improved clinical services, or launch an information campaign or other activity, here are the steps to follow and issues to consider when implementing services.

Identify priorities

- Consider how to increase access to services.
- Determine if you need to increase the number and types of postabortion care providers.
- Evaluate the quality of services.
- Consider increasing the range of reproductive health services available.
- Reflect on expanding PAC services to encompass as wide a range of procedures as possible.
- Explore attitudes and values of staff regarding provision of abortion and postabortion care and identify related training needs.

Set objectives

- Make sure that objectives are specific, measurable, achievable, realistic and time-bound.
- Consider the who, what, where, when, how and how much of each objective.
- Establish a clear timeline for achieving the objectives and plan a systematic evaluation of progress at specified times.

Develop a workplan

- Identify and define each main activity and list sub-tasks for each.
- Assign responsibility for each sub-task and a reasonable timeline for completion.
- Contact other interested partners and stakeholders in the community or government who can help achieve the objectives.
- Obtain necessary financial and material resources and determine ways to obtain sustainable resources.

Train staff at all levels

- Carry out values clarification exercises with all staff.
- Provide all staff with a general overview of postabortion care services.
- Provide specific training for medical staff to provide PAC and misoprostol for postabortion care.
Plan for high quality

- Decide on a system for monitoring the quality of programs and services.
- Develop a team approach to quality improvement with clear roles and responsibilities for all participants.

Plan for sustainability

- Obtain the support of key decisionmakers.
- Include program or service costs in the regular budget of the facility to ensure that you cover costs required for sustainability.
- Develop funding mechanisms, including cost recovery systems that reflect women’s ability to pay.
- Integrate or link postabortion care with existing reproductive health services.
- Devise an ongoing training program for clinical, administrative and management staff that introduces new skills and updates existing skills.
- Have regular meetings with staff to discuss progress and review suggestions for program improvement.
2.4 Ensuring sustainable supply of misoprostol

A discussion of contraceptive supply management in *The Family Planning Manager* (Management Sciences for Health 1992) highlights four key pieces of data as the basis of supply-related decisions:

1. Average monthly consumption – the amount of stock used each month
2. Losses – the amount of stock that is lost or otherwise not usable due to damage, expiration, or other reasons
3. Inventory – how much stock is on hand
4. Lead time – time between placement of an order and receipt of supplies at the service delivery point

It is important to use good supply management practices. The **FEFO** (first-to-expire, first-out) system explicitly tells managers to consume products based on expiration dates, ensuring that the oldest unexpired products are used first. Another commonly used and efficient system for supply management of contraceptive commodities is the **maximum/minimum system**. In this system, the minimum stock level is the level below which stocks should never drop without first having placed a new order. The maximum stock level is set to guard against oversupply and the loss of stock to expiration.

Storage costs for misoprostol are minimal, as it is the most stable of the uterotonic drugs (POPHI 2008). Misoprostol should be stored in a clean, dry, pest-free space. No refrigeration is necessary. Misoprostol should be protected from heat and humidity (POPHI 2008) and stored at normal room temperature (15-30°C or 59-86°F) in a closed container (POPHI 2007). Both in the pharmacy and at the facility, effectiveness of misoprostol will decrease if it is exposed to excess heat and moisture (POPHI 2007).

Because of the possibility of counterfeit drugs, it is best to use reliable distributors so you can be confident that manufacturers are complying with high standards in producing misoprostol for your market.

If your facility uses misoprostol for other indications (such as for the management of postpartum hemorrhage, the treatment of missed abortion, or labor induction), calculate the amount needed for each use separately. The uterus becomes more sensitive to misoprostol as pregnancy advances, so different regimens are required for different indications; much lower doses of misoprostol are given in advanced pregnancy (i.e., to induce labor).

---

8. The information contained in this section and Tool 2C is adapted from: Ipas. 2008. *MVA sustainable supply workbook*. Chapel Hill, NC: Ipas. These tools have not been field-tested for use in estimating supply needs for misoprostol use in postabortion care.
Determining the total amount of misoprostol required by a program or facility will depend on the indications for which misoprostol is being used, the typical expiration period on the product, product waste due to various reasons (e.g. expiry), storage conditions (which should be dry and at room temperature), and length of time to receive ordered supplies. You can use the formula in this tool to obtain a rough estimate of your supply needs. Please consider the misoprostol regimen you are using for each indication to calculate the final number of tablets needed. An excel spreadsheet to help you complete the calculations has been included on the CD accompanying this document (Annex 3 — Tool 2D: Estimating misoprostol supply needs spreadsheet) or can be requested via e-mail by contacting misoforpac@ipas.org.

Continued on next page ...
<table>
<thead>
<tr>
<th>Number of service days per month</th>
<th>Average daily caseload</th>
<th>Percentage of caseload using misoprostol</th>
<th>Misoprostol tablets needed per dose</th>
<th>How long does it take to receive misoprostol after you order it?</th>
<th>Average daily misoprostol caseload</th>
<th>Buffer to avoid stockout</th>
<th>Number of tablets forecasted to use per day</th>
<th>Number of tablets forecasted to use per month</th>
<th>Minimum misoprostol inventory level to maintain</th>
<th>Maximum misoprostol inventory level to attain</th>
</tr>
</thead>
<tbody>
<tr>
<td>Record the number of days services are provided.</td>
<td>Determine caseload based on last six months (if starting new services, base on two months of data to capture changing uptake; once more established, average based on six months of data).</td>
<td>Determine anticipated caseload percentage managed with misoprostol (may be 100 percent if only misoprostol is used for PAC; may be less if other methods are also available, such as MVA).</td>
<td>Based on indication and regimen used, # of pills per dose equals # of 200mcg misoprostol tablets needed per dose.</td>
<td>Record the number of weeks that typically elapse between order placement and delivery to your facility.</td>
<td>Equals (Average daily caseload) × (% of caseload using misoprostol)</td>
<td>Equals (Average daily misoprostol caseload) × (Misoprostol tablets needed per dose)</td>
<td>Equals (Average daily misoprostol caseload) × (Misoprostol tablets needed per dose)</td>
<td>Equals (Number of tablets forecasted to use per day) × (Number of service days per month)</td>
<td>Equals (Number of tablets forecasted to use per month) + (Buffer to avoid stockout)</td>
<td>If it takes less than 4 weeks to receive misoprostol after you order it, your maximum inventory level will equal 2 × (number of tablets forecasted to use per month). If it takes 4 weeks or longer, your maximum inventory level will equal 3 × (Number of tablets forecasted to use per month).</td>
</tr>
</tbody>
</table>

| Example of data and calculations | 30 | 4 | 65 | 3 | 2 | 3 | 126 | 9 | 270 | 396 | 540 |

Enter your facility's data in this row

* See Annex 3 on the accompanying CD for an excel spreadsheet that will help you complete the calculations.
2.5 Additional resources


3.1 Introduction

To implement a successful program using misoprostol for the treatment of incomplete abortion, a facility assessment can ensure that minimum requirements for service provision are met, regardless of the type of facility. In addition, a facility assessment can help determine the current quality of care and systems in place, which then can be compared to the minimum standards to see what, if anything, needs to be improved before starting a misoprostol program.

Module 3 provides guidance and tools for conducting the facility assessment, including examining the management and delivery of services, staffing, record keeping, equipment, supplies and facility infrastructure. If a facility already provides PAC services using other technologies such as manual vacuum aspiration (MVA), then many of the basic requirements may already be met. If your facility does not yet provide PAC services, review Tool 3A: Minimum requirements for treatment of incomplete abortion with misoprostol and determine what you need to meet the requirements. Remember that misoprostol treatment has very minimal service delivery requirements and can be provided almost anywhere.

If resources permit, a thorough assessment of your facility can also help you identify ways to improve quality of care. This includes

**ATTITUINAL OBSTACLES**

Abortion-related stigma is a social phenomenon based on values, beliefs and biases that may influence how clinicians treat women for incomplete abortion. Delays in care for the complications of unsafe abortions can cause death (Mayi-Tsonga et al. 2009). It is necessary to address root causes of abortion-related stigma to positively impact attitudinal obstacles to postabortion care. Values Clarification and Attitude Transformation (VCAT) interventions engage stakeholders to identify and address stigma-related barriers to service provision, as well as barriers to access and quality of care stemming from misinformation, values conflicts, negative attitudes and lack of respect for women’s rights. The facility assessment provides an opportunity to determine the VCAT needs of personnel at a particular site. For more information, see Abortion attitude transformation: A values clarification toolkit for global audiences (Turner and Page 2008) in the Additional Resources section at the end of this module.
reviewing the facility’s written policies, procedures and standards for all aspects of service delivery. You should also examine the financial and budgeting system in order to determine how you will purchase supplies and medicines related to the treatment of incomplete abortion with misoprostol (such as misoprostol, MVA, contraceptive supplies, and infection prevention supplies). Finally, determine the availability and schedule of staff able to provide postabortion care.

Program managers, clinicians, and other relevant stakeholders can all participate in using the facility assessment tool. It is generally most productive to establish a small team of people with different skills and perspectives to carry out the assessment; this can maximize the richness of the information gathered. For example, a relief agency may want to introduce misoprostol for treatment of incomplete abortion into health-care services in a refugee camp. In this instance, the facility assessment team might include the camp’s nurse manager, logistics and supplies manager, a representative from the refugee women’s group, and a staff member of the relief agency.

3.2 Models for integrating misoprostol into postabortion care services

**Introduction of misoprostol**

**Stand-alone primary care services**, including family planning clinics, can offer misoprostol for treatment of incomplete abortion whether or not MVA is available. However, there should be a referral link for MVA as a backup when needed. A misoprostol option at the lowest level of the health system allows clinicians to reach new populations of women and thereby expand points of service.

**Integration of misoprostol**

Integrating misoprostol treatment into existing PAC services allows women a choice of preferred technologies and potentially increases the number of clinicians able to offer PAC.

Integrating misoprostol treatment into emergency services such as emergency departments may also increase the number of clinicians able to offer PAC. Furthermore, it could decrease facility needs in terms of procedure rooms and equipment for care.

Integrating misoprostol treatment into basic and emergency obstetric and newborn care services has the advantage of further expanding the number of clinicians able to offer PAC. Furthermore, it links PAC services to maternal health services, which can capitalize on clinician skill sets and more comprehensively address women’s reproductive health needs.

**CONTRACEPTION: AN ESSENTIAL ELEMENT**

No matter what the model, contraceptive counseling and services are an essential component of PAC services for women who wish to delay or prevent pregnancy. Through the facility assessment, you can assess how contraceptive services can be improved to address women’s needs and provide more contraceptive choices. If the institution cannot offer a particular contraceptive method, identify other contraceptive providers in the community to whom women can be referred.
To implement misoprostol treatment in postabortion care services, it is important to understand the minimum requirements for service delivery. The minimum requirements listed below apply whether you are initiating new services or integrating misoprostol for postabortion care into existing services, and apply regardless of the level of service delivery. Please note that there are different requirements if you are providing MVA services. Any woman coming in with emergency conditions should be referred and treated within the general emergency obstetric care (EmOC) guidelines of your country.

<table>
<thead>
<tr>
<th>Minimum requirements for treatment of incomplete abortion with misoprostol</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Infrastructure and furniture</strong></td>
</tr>
<tr>
<td>❑ Counseling and examination room(s)</td>
</tr>
<tr>
<td>❑ Light (electricity not required, can be a flashlight)</td>
</tr>
<tr>
<td>❑ Toilet facilities</td>
</tr>
<tr>
<td>❑ Clean water supply</td>
</tr>
<tr>
<td><strong>Equipment and supplies</strong></td>
</tr>
<tr>
<td>❑ Supplies for pelvic and bimanual exam, including speculum and gloves</td>
</tr>
<tr>
<td>❑ Disinfection supplies for instruments and gloves</td>
</tr>
<tr>
<td><strong>Drugs and contraceptive supplies</strong></td>
</tr>
<tr>
<td>❑ Misoprostol</td>
</tr>
<tr>
<td>❑ Analgesics and antipyretics (nonsteroidal anti-inflammatory drugs such as ibuprofen and paracetamol)</td>
</tr>
<tr>
<td>❑ Contraceptive supplies</td>
</tr>
<tr>
<td><strong>Additional requirement for referral facilities:</strong></td>
</tr>
<tr>
<td><strong>Emergency treatment supplies</strong></td>
</tr>
<tr>
<td>❑ Emergency resuscitation materials and drugs (including IV lines and fluids, IV antibiotics, blood transfusion and other surgical supplies)</td>
</tr>
<tr>
<td>❑ Manual vacuum aspiration (MVA) equipment</td>
</tr>
<tr>
<td>❑ Other evacuation equipment if MVA is not available</td>
</tr>
</tbody>
</table>

Tool 3A. Minimum requirements for treatment of incomplete abortion with misoprostol
The facility assessment tool facilitates comprehensive site assessment. Conducting a thorough facility assessment will help you gather valuable information needed for introducing misoprostol for postabortion care services. Moreover, identifying and addressing gaps can help you improve quality of care. The tool does not prescribe specific goals but highlights key areas that are important in providing high quality service. However, these elements are not essential to providing misoprostol treatment. For example, although having a patient waiting area is preferable from a high quality standpoint (especially in a busy facility), it is not a requirement for service provision.

Depending on your role, you may use all or part of this assessment tool. You can also divide up sections of the tool among different members of the assessment team, with members addressing particular sections according to their expertise. District health managers may find this approach helpful for assessing primary care centers in their district. A clinician who wants to add misoprostol treatment to a rural health post may use sections of the tool to assess the site’s capacity to start services.

### I. FACILITY INFORMATION

| Name: | ____________________________________________ |
| Type (Public/Private): | ____________________________________________ |
| Assessors: | ____________________________________________ |
| Date: | ____________________________________________ |

Does this facility provide the following services?

<table>
<thead>
<tr>
<th>Service</th>
<th>Yes □</th>
<th>No □</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manual vacuum aspiration (MVA)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sharp curettage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy termination</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment of second-trimester abortion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contraceptive services</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

10. This tool was adapted from programmatic materials developed by Ipas Africa Alliance and Ipas Nigeria.
II. CLINIC LEADERSHIP AND MANAGEMENT
The support and understanding of facility managers and leaders on the issues and advantages of misoprostol for treatment of incomplete abortion is critical to successful services.

<table>
<thead>
<tr>
<th>Question</th>
<th>Answer</th>
</tr>
</thead>
</table>
| Are key facility managers supportive of the introduction of misoprostol for treatment of incomplete abortion services? | Yes ☐ No ☐ Don’t know ☐  
If no, please comment below: |
| What are clinicians’ and administrators’ attitudes and beliefs about who – such as doctors, midwives and nurses – should be trained in postabortion care services? | Comment: |
| What are staff perceptions of women who seek postabortion care – including subpopulations such as adolescent and young women? | Comment: |
| Are gender sensitivity and/or values clarification sessions needed and, if so, with whom? | Yes ☐ No ☐ Don’t know ☐  
Comment: |
### III. POSTABORTION CARE (PAC) SERVICE STATISTICS

The site should have a register for recording services. The record should be improved to capture PAC where this does not already exist.

<table>
<thead>
<tr>
<th>Question</th>
<th>Answer</th>
</tr>
</thead>
</table>
| Review logs, records and/or patient charts. How many postabortion complications were seen in the facility in the last three months? | Deaths: __________________________  
    Severe complications: ____________  
    Minor/moderate complications: ____________ |
| Do the records look complete (e.g. logbooks are filled out and up-to-date)? | Yes □ No □ |
| Is there a surveillance system for monitoring maternal deaths and other adverse events? | Yes □ No □ |
| What other information is routinely collected in the logbooks? | List:  
    ___________________________________________  
    ___________________________________________  
    ___________________________________________  |
| Is there a record or logbook for follow-up services and appointments? | Yes □ No □ |
| Is there a record of patient contact information for follow-up? | Yes □ No □ |
## IV. EQUIPMENT AND INFECTION PREVENTION

Presence of a laboratory, ultrasound or ability to provide MVA is not mandatory for a site to provide misoprostol for postabortion care services. However, a site without laboratory, sonography or MVA services should ensure that a referral network is in place when the services are required.

<table>
<thead>
<tr>
<th>Question</th>
<th>Answer</th>
</tr>
</thead>
</table>
| Is functioning manual vacuum aspiration (MVA) equipment available at the site? | Yes ☐  No ☐  
If yes, how many?  
If no, please explain limits to availability below: |
| Over the last six months, has the facility run out of infection prevention supplies? | Yes ☐  No ☐  
If yes, please explain what actions were taken. |
| Are protocols for processing and storing medical instruments being followed properly? | Yes ☐  No ☐  
If no, add additional details: |
| Does an appropriate system for medical waste disposal exist? | Yes ☐  No ☐  
Please describe: |
| **If this is a referral site**, does the facility have the following? | STI testing Yes ☐  No ☐  
Urinalysis Yes ☐  No ☐  
Bacteriologic cultures Yes ☐  No ☐  
Hemoglobin and hematocrit Yes ☐  No ☐  
Blood grouping and cross-matching Yes ☐  No ☐  
Ultrasound Yes ☐  No ☐  
Facilities for blood transfusion Yes ☐  No ☐  
Intravenous fluids Yes ☐  No ☐ |
**V. PHARMACY AND CONTRACEPTION**
The presence of a pharmacy is not mandatory for a site to provide misoprostol treatment for incomplete abortion. Where a pharmacy is lacking, however, the site should have secure cabinets for storing misoprostol as well as analgesics and, preferably, contraceptives.

<table>
<thead>
<tr>
<th>Question</th>
<th>Answer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Is misoprostol available in the clinic?</td>
<td>Yes ☐  No ☐</td>
</tr>
<tr>
<td>Does the clinic provide contraceptives with postabortion care services (in other words, can the woman obtain contraceptive services without having to wait)?</td>
<td>Yes ☐  No ☐</td>
</tr>
<tr>
<td>If yes, list all methods available:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>What instructions do women receive for contraceptive method resupply?</td>
<td>Describe:</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Does this site have its own drug storage area where drugs can be dispensed or stored?</td>
<td>Yes ☐  No ☐</td>
</tr>
<tr>
<td>If yes:</td>
<td></td>
</tr>
<tr>
<td>› Is the storage area locked?</td>
<td>Yes ☐  No ☐</td>
</tr>
<tr>
<td>› Who has access to the cabinet/is responsible for drug dispensation?</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>If no:</td>
<td></td>
</tr>
<tr>
<td>› Do they refer to another part of this facility?</td>
<td>Yes ☐  No ☐</td>
</tr>
<tr>
<td>› Do they refer to a different facility?</td>
<td>Yes ☐  No ☐</td>
</tr>
<tr>
<td>Do patients pay for drugs or contraceptives?</td>
<td>Yes ☐  No ☐</td>
</tr>
</tbody>
</table>
## VI. CLINIC SET-UP

Basic standards for providing misoprostol treatment as stipulated by the country’s local authorities should be followed. The following are examples of what to check.

<table>
<thead>
<tr>
<th>Question</th>
<th>Answer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Do women have to pay for PAC treatment?</td>
<td>Yes □  No □</td>
</tr>
<tr>
<td>If yes, what is the cost of PAC treatment?</td>
<td></td>
</tr>
<tr>
<td>Cost of misoprostol treatment:</td>
<td>________</td>
</tr>
<tr>
<td>Cost of MVA treatment:</td>
<td>______________</td>
</tr>
<tr>
<td>Cost of another procedure (indicate):</td>
<td></td>
</tr>
<tr>
<td>Is there a waiting area?</td>
<td>Yes □  No □</td>
</tr>
<tr>
<td>What are the typical or likely waiting times for services?</td>
<td>Treatment with misoprostol: __________</td>
</tr>
<tr>
<td>MVA: ______________</td>
<td></td>
</tr>
<tr>
<td>Contraceptive services: __________</td>
<td></td>
</tr>
<tr>
<td>Other: ______________</td>
<td></td>
</tr>
<tr>
<td>Are waiting, treatment and recovery areas private, comfortable and adequate?</td>
<td>Yes □  No □</td>
</tr>
<tr>
<td>If no, please comment:</td>
<td></td>
</tr>
<tr>
<td>Does the facility have a space where women can wait after taking the misoprostol tablets, if they choose to stay? Note: Women may choose (but are not required) to stay in the facility for one to two hours after taking misoprostol.</td>
<td>Yes □  No □</td>
</tr>
<tr>
<td>If yes, describe the available space:</td>
<td></td>
</tr>
</tbody>
</table>
What, if any, changes or renovations are needed to facilitate smooth patient flow?\(^{11}\)

<table>
<thead>
<tr>
<th>Describe:</th>
</tr>
</thead>
</table>

Is there a patient toilet facility?  
Yes □ No □  
If yes, is there a sign to the toilets?  
Yes □ No □

Is there clean water?  
Yes □ No □

Are there pads or other supplies for bleeding?  
Yes □ No □

If women are sent home to take the medications, are they given clear written instructions about how to use misoprostol, what to expect, danger signs and where to go in the case of complications?  
Yes □ No □  
If yes, are they available in the local language(s)?  
Yes □ No □  
If yes, are they appropriate to the literacy and education levels of patients?  
Yes □ No □

Are trained staff on duty during each shift?  
Yes □ No □

Do service providers have access to a telephone 24 hours a day?  
Yes □ No □  
If no, please explain hours or other limitations:

Is there 24-hour coverage at the facility?  
Yes □ No □

Is there an established referral relationship with another facility for complications beyond the facility’s capability to manage?  
Yes □ No □  
If yes, please write:  
Name of referral facility:  
Location:  
Contact information:  
______________________________________________________________________________  
______________________________________________________________________________

\(^{11}\) For additional information on how to conduct a client flow analysis, consult: EngenderHealth. 2009. COPE® for comprehensive abortion care service: A toolbook to accompany the COPE® handbook. New York: EngenderHealth.  
VII. STAFF CAPACITY AND TRAINING NEEDS

For the site to provide misoprostol, the staff should be well trained. Although staff do not need to be experienced in other uterine evacuation methods, they should receive an orientation to manual vacuum aspiration if MVA is offered at the site.

<table>
<thead>
<tr>
<th>Ask clinicians whether they perceive the facility to be well prepared in the following areas:</th>
<th>Present and adequate</th>
<th>Present but needs upgrading</th>
<th>Absent, training needed</th>
</tr>
</thead>
<tbody>
<tr>
<td>General experience and training in reproductive health (including STIs, HIV, violence screening, and other areas)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Experience assessing patients for early pregnancy and incomplete abortion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Experience with postabortion counseling, including contraceptive counseling and method provision after postabortion care</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Knowledge of procedures for informed consent and referrals in line with women's rights and confidentiality</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Understanding of regulatory issues and the ethical and legal mandate for provision of abortion and postabortion care</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Knowledge and practice of infection prevention standards</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Knowledge of institutional protocols on incomplete abortion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Knowledge of contraception after misoprostol treatment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Experience with manual vacuum aspiration (MVA)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Please list the number of each type of staff trained to use MVA: | ________(#) doctors  
________(#) midwives/nurses  
________(#) health officers  
________(#) other types of clinicians |
| Please list the number of each type of staff trained to use misoprostol: | ________(#) doctors  
________(#) midwives/nurses  
________(#) health officers  
________(#) other types of clinicians |
| Please list the number of personnel trained on patient stabilizing and referral for complicated cases: | |
| Assess the site’s training capacity, including current in-service training activities: | |

**Additional comments and recommendations for misoprostol introduction:**

___________________________________________________________________________________
___________________________________________________________________________________
___________________________________________________________________________________
___________________________________________________________________________________
___________________________________________________________________________________
3.3 Using the results of the facility assessment tool

Once your team has used the facility assessment tool to collect information, you should analyze the results to determine the facility’s capacity for misoprostol service delivery. It can also be helpful to present the assessment results to the facility staff, highlighting both the positive results and areas that could improve or change. Your team may want to continue to talk with staff to further explore the reasons why gaps exist. This may help to overcome barriers and identify solutions.

Key site leaders and staff providing services at the facility should prioritize needed changes and develop an action plan to strengthen the facility’s capacity to provide misoprostol for postabortion care. Teams may want to set specific benchmarks with timelines and goals. For example, if increasing contraceptive commodity choices has been identified as a need, a team could indicate that more method choices should be available by the second quarter, with 25 percent more contraceptive uptake by the fourth quarter. Assigning a specific staff person for the management of selected goals will help ensure that they are addressed.

There are many other approaches to using assessment data to plan for a change, ranging from the simple to the highly complex. Use whatever works best for your site, given the resources, commitment and capacity of all involved. For additional tools, approaches, and resources, see the PRIME II project toolkit on performance improvement: http://www.intrahealth.org/sst/intro.html.

3.4 Additional resources


4.1 Introduction

Community participation is a key component of primary health care. Meaningful participation includes the ability to influence decision-making processes regarding health services. Communities can play a key role in reducing maternal mortality and morbidity when they establish links with facilities that offer reproductive health services, and with clinicians concerned about women’s health. Community members — including women, health-care providers, community leaders, family members and others — are generally already invested in the health, safety and well-being of local women and families.

Partnerships between health facilities, trained clinicians and community leaders and groups can greatly strengthen the delivery of high quality, woman-centered postabortion services in the local communities where women live (thereby fulfilling women’s rights and saving lives). Such partnerships, though not strictly essential to service delivery, can contribute to implementation of high quality services that meet women’s needs. Module 4 is designed to aid you, as a clinician or facility manager, to enhance community-facility relationships to strengthen service delivery. It will help you identify potential partners and explore opportunities for collaborating and working with local communities to make services available, accessible, and high quality.

Involving community members after a facility has initiated services can increase acceptance, use of, and involvement in services. Early community involvement along with ongoing community dialogue can help promote services that are consistent with the community’s needs and desires. This type of engagement will help greatly in identifying and addressing the root causes of unsafe abortion in a given community.

DEFINING COMMUNITY
Many diverse communities can exist within a geographic location. They can be defined on the basis of specific, shared interests, or among people with a common history, language, culture, or shared social, political or economic realities or interests. When serving a geographic area, it is important to address the needs and desires of all communities in the area, including, for example, young, poor, migrant and other populations with specific needs.

TARGET AUDIENCES: Clinicians and facility managers

TOOLS IN THIS MODULE:
4A Quick community assessment guide
4B Potential audiences and topics for information, education and communication on misoprostol use in postabortion care

4.2 Partnering to reach communities

In establishing linkages with communities, you should consider partnering with local groups, NGOs and community-based organizations. Successful collaborative partnerships can support community members who champion and advocate for high quality, sustainable programs. In addition, partnering with community-based organizations can give a voice to typically marginalized or disenfranchised populations, such as youth or women living with HIV/AIDS.

By engaging local partners, you can build on existing local networks to disseminate information, mobilize community members and ensure other forms of community buy-in. To begin to create links, identify and talk with key individuals who represent the shared interests of broader communities. These might include:

- Local government representatives
- Health committee members
- Leaders of women’s groups
- Leaders of men’s groups
- Leaders of youth groups
- Faith-based leaders
- Traditional leaders
- Heads of institutions
- Law-enforcement officials
- Traditional birth attendants
- Traditional medicine healers
- Community-based health workers

To build effective partnerships, the roles of each partner must be clearly defined and agreed upon. This is especially useful when defining a plan of action, expectations and desired outcomes. In addition, identifying the most appropriate community group with which to partner is important to the success of the partnership. If you are interested in additional resources or technical assistance to help identify the organizations best suited to improving knowledge of and access to health services, please contact misoforpac@ipas.org.

PROMOTING UNDERSTANDING OF YOUR LEGAL CONTEXT

Most countries have some legal indications for abortion, even if limited (for example, rape or incest, or to save a woman’s life). When you design services or implement partnerships with communities, make sure to adapt your messages to educate community members about the legal indications for abortion as well as information on postabortion services. Communities should be aware of the legal indications for abortion and women must know where to obtain safe services.
A focused community assessment can be used to determine where women receive reproductive health information and services, which reproductive health services women have access to, what existing health structures and mechanisms are in place, what is important to women and their families, and what is relevant to their real-life circumstances. This information can then be used to reach women with postabortion care information and services. This short assessment guide outlines some of the key questions to consider when you are designing a community outreach initiative. Partners can help to answer these key questions.

**Health information**

- Where do women obtain health-related information?
- Where do women get information on reproductive health including information on pregnancy, contraception and unwanted pregnancy?
- Are there any common rumors or myths about contraception?

**Contraceptive services**

- What methods of contraception are available in the community?
- Where do women get contraceptive services?

**Unwanted pregnancy**

- What do women in your community do when faced with an unwanted pregnancy?

**Abortion and postabortion care practices and services**

- Is abortion legal? Under what circumstances?
- What are the common abortion methods used by women in the community (for example, herbs, brews, or medicines)?
- What methods are currently available for treating incomplete abortion in the community?
- What resources, such as community-based health agents, are available in the community to facilitate access to misoprostol for postabortion care services?

**Attitudes and barriers**

- Do community members know where postabortion care services are available?
- What barriers exist to accessing postabortion services (for example, financial and geographic barriers)?
- How can access to treatment of incomplete abortion be improved?
- What are the local beliefs or norms around women having an abortion or treatment for postabortion complications?
- What are local beliefs or attitudes about clinicians who offer postabortion care services?
How does abortion-related stigma influence women's health and what kinds of barriers does it create to accessing services?

Which key institutions and players should be involved in addressing abortion-related stigma to overcome stigma-related barriers in the community?

Who are the key leaders and change agents in the community?
4.3 Strategies for working with communities

Community linkages are most effective when they are locally driven, and championed by recognized community leaders (who can provide credibility and sustainability) and community members (who will use the services). Working with your community partners, you can use the information gathered in the community assessment to design strategies that will link postabortion services and community members in effective ways. Community partners can help identify community needs and existing structures that can be used to inform these service provision strategies. It is important to be open to implementing community-generated solutions to identified problems, recognizing that these solutions may change over time.

Tool 4B: Potential audiences and topics for information, education and communication on misoprostol use in postabortion care offers suggested methods of achieving meaningful community participation, as well as topics for dialogue that may be a useful starting point. Remember:

- Although strategies for involving community members in health care vary, it is important to build community members’ capacity not only as beneficiaries of health care, but as partners and leaders for good health.

- It is important to set and prioritize topics with community members. Make sure the needs of special populations (such as poor, young, HIV-positive, refugee and migrant populations) are taken into consideration, too.

- Preferred methods and prioritized topics may change over time. It is therefore important to continuously seek community input when making changes to service delivery or health messages.

ADDRESSING STIGMA

Stigma surrounding pregnancy termination often results in practices shrouded in secrecy and shame. Stigma and its manifestations also represent key barriers to women’s access to safe postabortion care. Identifying social norms that stigmatize abortion and postabortion care and reducing abortion-related stigma are essential to ensuring that all women are able to exercise their reproductive health rights. Stigma must be addressed at various levels with gatekeepers and opinion leaders, community groups, abortion care providers and individual women and men to find ways to mitigate its impact, create awareness and understanding of the harm it causes, and block its perpetuation.
### Audience

<table>
<thead>
<tr>
<th>Community members:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adolescents, adults, and their partners, family members, or guardians; teachers, women's groups, men's groups, youth leaders, union leaders, and members; and organizations such as community groups, unions, and others.</td>
</tr>
</tbody>
</table>

| Taxi drivers or other local informants such as traditional birth attendants and community health workers. |

### Topics

<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Unwanted pregnancy: Signs, symptoms, and causes of unwanted pregnancy and the importance of seeking early assistance.</td>
</tr>
<tr>
<td>Postabortion care: Information about postabortion care, including how and where to get it.</td>
</tr>
<tr>
<td>Pregnancy prevention: Information about emergency contraception and its importance.</td>
</tr>
</tbody>
</table>

### Communication avenues

<table>
<thead>
<tr>
<th>Media</th>
</tr>
</thead>
<tbody>
<tr>
<td>Presentations</td>
</tr>
<tr>
<td>Workshops</td>
</tr>
<tr>
<td>Face-to-face discussions and informal meetings</td>
</tr>
<tr>
<td>Interpersonal communication activities (drama, song, poetry, dance, talks, face-to-face discussions)</td>
</tr>
<tr>
<td>TV</td>
</tr>
<tr>
<td>Radio</td>
</tr>
<tr>
<td>Print and electronic media (newspapers, magazines, posters, flyers, websites)</td>
</tr>
</tbody>
</table>

### Access to PAC

- Health service facilities
- Schools and universities
- Workplaces
- Youth centers
- Women's centers
- Group meetings
- Village/community meetings (traditional and formal)
- Markets
- Discos, clubs, and bars
- Health fairs
- Internet
- Professional meetings and conferences
- Workshops/conducted by health professionals
- Workshops conducted by informal organizations (women's organizations, faith leaders, community leaders)
| Policymakers: Health system officials, legislators and others | **Unwanted pregnancy:** Prevalence, health and resource impact of unsafe abortion and unwanted pregnancies on women and families; the health impact of timing and spacing of pregnancies; relative costs to families and the community of maternal morbidity and mortality due to unwanted pregnancy and unsafe abortion; importance of educating constituents to prevent unwanted pregnancies, recognize the signs and symptoms of pregnancy, seek care early, identify pregnancy complications, know where and when to seek help, understand the importance of timing and spacing pregnancies, and understand the dangers of unsafe abortion.  

**Postabortion care:** Postabortion care laws and service policies; women’s (including adolescents’) rights regarding postabortion care; relevant postabortion care access issues, including access to and availability of misoprostol, and the impact on health and resources; relative costs of providing emergency treatment for unsafe abortion compared with those of safe induced abortion and contraception; availability of drugs (misoprostol) to treat incomplete abortion; need to legislate for funding of high quality reproductive health services for women, including postabortion care services.  

**Pregnancy prevention:** Information about modern methods of contraception (including emergency contraception); safety and effectiveness; the importance of timing and spacing pregnancies. | • Conferences  
• Governmental hearings  
• In-person meetings | • Research reports for meetings and legislative hearings  
• Communications to the staff of these officials  
• Workshops/presentations  
• Letter-writing campaigns  
• News media (national newspapers, magazines, news broadcasts/current affairs programs) |
| --- | --- | --- |
| Health workers: Clinicians (doctors, midwives, nurses, pharmacists, and others)  
Traditional healers or practitioners | **Unwanted pregnancy:** Importance of educating and counseling women on preventing unwanted pregnancies, recognizing the signs and symptoms of pregnancy, seeking care early, identifying pregnancy complications, knowing where and when to seek help, understanding the importance of timing and spacing pregnancies, and understanding the dangers of unsafe abortion.  

**Postabortion care:** Postabortion care laws and service policies; women’s (including adolescents’) rights regarding postabortion care; legal and ethical obligations regarding provision of abortion and/or postabortion care; integrated provision of PAC services and contraception; emergency contraception; the importance of timing and spacing pregnancies; addressing women’s other reproductive health needs; how to obtain and convey information to community groups (such as those listed above); where to refer women with pregnancy complications and/or incomplete abortion; the importance of seeking care early and providing high quality services; ensuring patient confidentiality and providing adequate counseling where/how to get trained in postabortion care.  

**Pregnancy prevention:** Information about modern methods of contraception (including emergency contraception); safety and effectiveness; referrals to other reproductive health services; the importance of timing and spacing pregnancies. | • Professional meetings and conferences  
• Professional publications  
• Village/community meetings  
• Workplaces  
• Trainings | • Professional/peer-reviewed journals  
• Workshops/presentations  
• Print and electronic media (newspapers, magazines, posters, flyers, websites)  
• Interpersonal communication activities (talks, face-to-face discussions) |
4.4 Additional resources


5.1 Introduction

Once you have planned to provide care with misoprostol for incomplete abortion, you will need to focus on the practical keys to implementing the service and delivering high quality care. Module 5 provides you with clinical information and tools to integrate misoprostol treatment into existing reproductive health services for women. The module contains information on misoprostol, management of side effects and potential complications, preparing women for what to expect, follow-up care and contraception. **Tool 5A** is an abbreviated, step-by-step clinical protocol to be used as the essential protocol for clinicians.15

5.2 Misoprostol: what it is and how it works

Misoprostol is a prostaglandin E1 analogue. It causes the cervix to soften and the uterus to contract. Misoprostol has several uses in obstetrics and gynecology, which include treatment of incomplete abortion and miscarriage; treatment of missed abortion (including intrauterine fetal death); labor induction; prevention and treatment of postpartum hemorrhage; cervical priming; and pregnancy termination (FLASOG 2007, Goldberg et al. 2001, Weeks and Faundes 2007, WHO 2003).16 Because the uterus becomes much more sensitive to the effects of misoprostol as pregnancy advances, doses of misoprostol for labor induction are much lower than doses for first-trimester treatment of incomplete abortion (see **Tool 5E: Dosage card**). For more information on misoprostol’s different uses, please visit www.misoprostol.org.

5.3 Regimens and efficacy of misoprostol treatment for incomplete abortion

For the purposes of standardization and to avoid confusion, it is advisable that local experts and authorities select **one misoprostol regimen** for the treatment of incomplete abortion to use in their country. Sublingual and oral routes of misoprostol administration have the quickest onset of action and have been widely studied. Misoprostol 400mcg sublingually and misoprostol 600mcg orally have similar safety and efficacy profiles when used with uterine size less than or equal to 12 weeks LMP (last menstrual period) (see **Table 1 and Tool 5E: Dosage card** (Diop et al. 2009, Gynuity Health Projects 2009, Tang et al. 2007)).

---

15. "Clinicians", in this context, refers to any trained health-care provider, such as physicians, midwives, nurse-practitioners, clinical officers, physician assistants and others.

Table 1. Misoprostol for incomplete abortion – doses and regimens

<table>
<thead>
<tr>
<th>Uterine size</th>
<th>Misoprostol dose</th>
<th>Route</th>
<th>Timing</th>
<th>Success (%)</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>400mcg</td>
<td>Sublingual</td>
<td>Two 200mcg tablets under the tongue for 30 minutes, then swallow the remaining pill fragments.</td>
<td>95-98</td>
<td>(Dabash et al. 2010, Diop et al. 2009)</td>
</tr>
</tbody>
</table>


5.4 Misoprostol for the treatment of missed abortion and anembryonic gestation

Although this toolkit focuses on the indication of misoprostol for the treatment of incomplete abortion, misoprostol, as noted, can also be used for the treatment of missed abortion and anembryonic gestation. Missed abortion is characterized by the arrest of embryonic or fetal development; anembryonic pregnancy (formerly called blighted ovum) is when a gestational sac develops but there is no embryo within it. Embryonic demise occurs when an embryo has no cardiac activity. Both conditions are diagnosed by ultrasound. The dosage for missed abortion and anembryonic gestation is misoprostol 800mcg vaginally or misoprostol 600mcg sublingually every three hours for a maximum of three doses. A single sublingual dose of misoprostol 600mcg may also be effective. However, treatment of missed abortion with sublingual misoprostol has not been widely studied.

Because both types of early pregnancy loss involve little to no bleeding and a closed cervix, misoprostol treatment is not as effective for these indications as it is for incomplete abortion. Reported success rates for misoprostol treatment of missed abortion vary widely. For more detailed information about the reported use of misoprostol for missed abortion, see Gynuity Health Projects’ *Misoprostol for treatment of incomplete abortion: An introductory guidebook* at http://gynuity.org/resources/info/guidebook-on-misoprostol-for-treatment-of-incomplete-abortion/.

17. Success is defined as complete uterine evacuation without further intervention with vacuum aspiration or curettage.
Tool 5A.

Misoprostol for treatment of incomplete abortion: Basic clinical protocol

For rapid assessment of patients in emergency, see section VIII of this tool: Emergency assessment and care

I. Eligibility

A. Women with the following conditions are eligible for misoprostol:
   1. Open cervical os
   2. Vaginal bleeding or history of vaginal bleeding during this pregnancy
   3. Uterine size at or under 12 weeks LMP

B. Contraindications
   1. Known allergy to misoprostol or to other prostaglandins
   2. Confirmed or suspected ectopic pregnancy
   3. Signs of sepsis or active pelvic inflammatory disease
   4. Hemodynamic instability or shock

C. Precautions (treatment dependent on clinical judgment and available options for safe postabortion care)
   1. IUD in place: remove before beginning the regimen
   2. Hemorrhagic disorder or current anticoagulant therapy
      Note: In general, it may be safer for women with hemorrhagic disorder or who are taking anticoagulants to receive care in a health facility where they can be observed and monitored; vacuum aspiration (if available) may be the safer treatment choice.
   3. Uterine size larger than 12 weeks
   4. Severe anemia
   5. Women who are breastfeeding may take misoprostol.

II. Clinical history and examination

A. Obtain history
   1. Current medicines used
   2. Known allergies
   3. Acute or chronic illnesses or conditions
   4. Brief obstetric and contraceptive history
   5. History of current pregnancy
a. LMP  
b. Pregnancy symptoms  
c. When bleeding began, bleeding patterns and amount of bleeding  
d. Pelvic pain/cramping  
  • Is pain/cramping intermittent (like contractions) or constant?  
  • Severity of pain/cramping on a scale of 1 to 10 (10 = “worst pain I’ve ever felt”)

B. Carry out ancillary testing (if indicated and available)  
1. Hemoglobin or hematocrit  
2. Ultrasound: not routinely needed to diagnose incomplete abortion  
3. Pregnancy testing: not routinely needed to diagnose incomplete abortion  

C. Perform physical exam  
1. Obtain vital signs: blood pressure, temperature, pulse  
2. Assess general appearance: pallor, level of energy and alertness, ambulatory, no indication of acute distress  
3. Perform pelvic exam and assess:  
   a. Uterine size, tenderness  
   b. Cervical motion tenderness  
   c. Adnexal mass suggestive of ectopic pregnancy  
4. Perform speculum exam and assess:  
   a. Cervical os (open or closed)  
   b. POC protruding from cervix  
   c. Discharge from os  
   d. Blood in vaginal vault (color and amount)  

III. Assessment  
A. Assess whether the woman is in stable condition.  
B. Ascertain whether a diagnosis of incomplete abortion is warranted.  
C. Assess whether the woman is an eligible candidate for misoprostol treatment.  

IV. Treatment  
A. Discuss treatment options with women determined to be eligible: misoprostol, MVA, expectant management or other.  
B. If the woman decides to use misoprostol treatment:
1. Explain what to expect:
   a. Effectiveness of treatment (91-99 percent)
   b. How misoprostol is used
   c. Range of normal experience
   d. Potential side effects and complications
   e. Warning signs to seek help
   f. Access to emergency care if needed
   g. Contraceptive needs

2. Provide misoprostol. Depending on the space available at the facility, the woman’s condition and her preference, she can take the medicines at the clinic and then return home, she can take the misoprostol at home, or (if the facilities permit and this is the woman’s preference) she can remain in the clinic for several hours for observation. To avoid confusion, choose one regimen for your program (either one may be given):
   a. **Oral misoprostol: 600mcg**
   OR
   b. **Sublingual misoprostol: 400mcg**

3. Provide additional medicines:
   a. For pain: NSAIDs such as ibuprofen 400-600mg orally every six hours as needed
   b. Other medicines (for example, antiemetics) as needed

V. **Warning signs for which women should seek immediate medical care**

A. **Heavy bleeding**
   1. Soaking two full-thickness sanitary pads per hour for two consecutive hours
   2. Heavy bleeding that occurs after bleeding had slowed down or stopped
   3. Feeling light-headed, dizzy or weak as bleeding continues

B. **Fever that lasts more than a day or starts any day after the misoprostol is taken**

C. **Severe pain, even on the day of taking misoprostol, that does not get better with medication, rest or a heating pad**

D. **Feeling very sick**

VI. **Contraception**

A. Oral contraception, contraceptive implants, skin patches, the vaginal ring or contraceptive injectables can be given at the clinic on the day misoprostol is given.

B. Intrauterine contraception can be provided when successful treatment is confirmed at follow-up.
C. Condoms, diaphragm, contraceptive jellies, foam or film can be given on the day misoprostol is given.

D. Emergency contraceptive pills should be given in advance as a back-up method.

E. Sterilization can be provided at the follow-up visit.

VII. Follow-up visit

A. Schedule a follow-up visit one to two weeks following misoprostol administration.

B. History suggestive of successful treatment:
   1. Woman experienced bleeding ranging from lighter than a menstrual period to much heavier than a menstrual period after taking misoprostol, usually with passage of clots or tissue.
   2. Pregnancy symptoms have lessened or disappeared; she no longer feels pregnant.

C. Physical exam suggestive of successful treatment:
   1. Minimal or absent bleeding
   2. Normal uterine size (small, firm)
   3. Non-tender uterus and adnexae and no cervical motion tenderness
   4. Closed cervical os

D. If findings show that abortion may still be incomplete and the woman is clinically stable, she may be offered:
   1. Observation with expectant management (one to two weeks)
   2. A repeat dose of misoprostol. If the woman is treated with a repeat dose of misoprostol, it is advisable that she be evaluated again in one to two weeks to be sure the abortion is complete.
   3. If the patient requests completion or in the event of infection or clinically significant bleeding, vacuum aspiration should be provided.

VIII. Emergency assessment and care

A. Rapid initial assessment for shock if woman appears to be frankly hemorrhagic, losing consciousness, near collapse, septic, etc.
   1. Check vital signs (blood pressure, pulse, temperature, respiratory rate)
   2. Signs of shock:
      a. Fast, weak pulse (rate > 110 beats per minute)
      b. Low blood pressure (diastolic <60)
      c. Pallor (generally very pale, pallor of palms or around the mouth)
      d. Sweatiness
      e. Rapid breathing (respiration > 30 per minute)
f. Anxiousness, confusion or unconsciousness

g. Frank, profuse hemorrhage

B. If the woman is in shock or clinically unstable:

1. If woman is conscious or a family member is present, find out:

   a. If woman is on current medications
   
   b. If woman has a serious health condition
   
   c. If woman has known allergies

2. Proceed immediately to stabilize the woman

   a. IV fluid volume replacement with large-bore IV catheter
   
   b. Oxygen by mask if available
   
   c. If sepsis is suspected, blood and cervical cultures if possible
   
   d. Broad-spectrum IV antibiotics if indicated
   
   e. Uterine evacuation as soon as possible if indicated
   
   f. Determine underlying etiology of shock (for example, a ruptured ectopic pregnancy would require emergency surgery).

C. Transfer to acute-care facility

1. If woman requires transfer to facility that can provide higher-acuity care, she may need stabilization and volume replacement with IV fluids before/during transport.

2. Notify referral facility that woman is being transported and give report on her diagnosis and condition.

---

A longer version of this protocol with references can be found in Annex 1: Clinical assessment reference guide: Overview of misoprostol for the management of incomplete abortion.
This Clinical flow chart can be used to provide a general overview of the key components of postabortion care service provision.

**Tool 5B. Clinical flow chart**

**Woman presenting with signs and symptoms of incomplete abortion**

**Eligible for misoprostol**
- Open cervical os
- Vaginal bleeding
- Uterine size at or under 12 weeks LMP

**Ineligible for misoprostol**
- Known allergy to misoprostol or other prostaglandins
- Confirmed or suspected ectopic pregnancy
- Signs of sepsis or active pelvic inflammatory disease
- Hemodynamic instability or shock

**Choose treatment for incomplete abortion**

**Perform MVA**

**Administer misoprostol**
- 600mcg orally (single dose)
- OR
- 400mcg sublingually (single dose)

**Carry out expectant management**

**Provide contraceptive counseling**

**Provide follow-up**

**Refer for further assessment or emergency treatment**
Tool 5C.
Service delivery diagram

Below is a sample flow chart for the integration of misoprostol into all levels of service delivery with referrals to appropriate facilities based on assessment results.

**Health facility without MVA**
- **Uterine size ≤12 weeks LMP**
  - Administer misoprostol*
  - Refer women who are clinically unstable or who have severe complications
- If medical management fails and woman is clinically stable
  - Expectant management
  - OR
  - Repeat misoprostol

**Health facility with MVA**
- **Uterine size ≤12 weeks LMP**
  - Administer misoprostol*
- **Uterine size >12 weeks LMP**
  - MVA or refer for severe complications
- If medical management fails and woman is clinically stable
  - Expectant management
  - OR
  - Repeat misoprostol
  - OR
  - Treat with MVA

**Referral facility**
- **Uterine size ≤12 weeks LMP**
  - Administer misoprostol*
- **Uterine size >12 weeks LMP**
  - MVA or other uterine evacuation methods, surgery or other procedures to treat complications as needed
- If medical management fails and woman is clinically stable
  - Expectant management
  - OR
  - Repeat misoprostol
  - OR
  - Treat with MVA

**Contraceptive counseling and method provision**
- REFER IF NECESSARY

* Check eligibility. Misoprostol regimens are 600mcg oral or 400mcg sublingual.
Clinicians may adapt these charts as needed, or integrate the information into existing charts. More information on using data gathered from the charts for monitoring purposes is included in Module 6: Ensuring high quality services. Additional resources for more detailed patient charts at the tertiary level can be found elsewhere.\(^1\)

**PATIENT CHART FOR MISOPROSTOL USE IN POSTABORTION CARE**

Name: ___________________________  Date: ___________________________

Age: ___________________________  Contact information: ___________________________

Referred from (facility name and site): ___________________________________________

Reason for referral: ___________________________________________________________
Medical and obstetric history

- Date of last menstrual period: _____ / _____ / _____
  Uterine size: _____ (weeks) _____ (days)
- Vaginal bleeding?  Yes □  No □  Duration ____________________________
- Pelvic pain or cramping?  Yes □  No □
- Passed tissue or products of conception?  Yes □  No □
- Was she using a contraceptive when she got pregnant this time?*  Yes □  No □
  Specify type: ___________________________________________________________
  *If IUD in place, remove before administering misoprostol.
- Current medications: ___________________________________________________
- Known allergies to drugs or other agents?  Yes □  No □
  List: ___________________________________________________________________
- History of anemia or bleeding/clotting disorders?  Yes □  No □
  Describe: __________________________________________________________________
- Surgical history?  Yes □  No □
  Describe: ___________________________________________________________________
- Any other health conditions?  Yes □  No □
  List: ___________________________________________________________________

Physical exam

- Vital signs:
  Blood pressure: _________________________ Pulse: _________________________
  Temperature: _________________________ Respiratory rate: _________________________
- Uterus:
  Size: _______________________________ Tenderness: _______________________________
- Cervical motion tenderness?  Yes □  No □
- Adnexa:
  Masses: _______________________________ Tenderness: _______________________________
- Speculum exam done?  Yes □  No □
Specify any abnormal signs (*cervical tears, foreign objects, bleeding visualized, other abnormal sign*)

- Cervix:
  Os:  Open □  Closed □
  Blood in vaginal vault: Amount/color:____________________________________________________
  Mucopurulent discharge:  Yes □  No □

**Treatment**

- Diagnosis:
  □ Incomplete abortion (uncomplicated case)
  □ Incomplete abortion (complicated case: shock, signs of infection, cervical tears, foreign objects, other complication)
  □ Other: _______________________________________________________________

If incomplete abortion, check method used for treatment.

  □ Misoprostol: _________  Dose: _______ (# of tablets)  Route:________________________
  □ MVA
  □ Expectant management
  □ Other: _______________________________________________________________
  □ Referred

- For referrals:
  Reason for referral (specify): ________________________________________________
  Place of referral (specify): ________________________________________________

- Medications provided at discharge (check as appropriate):
  a) Analgesic: ___________________  ___________________  ___________________
     (medication name)  (dosage)  (route)
  b) Antibiotic: ___________________  ___________________  ___________________
     (medication name)  (dosage)  (route)
  c) Antipyretic: ___________________  ___________________  ___________________
     (medication name)  (dosage)  (route)
  d) Other (specify): ___________________  ___________________  ___________________
     (medication name)  (dosage)  (route)
Plan to confirm pregnancy expulsion and follow-up as necessary.

Date woman will return for follow-up: ________________________________

**Contraceptive counseling**

- Contraceptive counseling provided?  Yes ☐  No ☐
  Contraceptive method provided at this visit (specify): ________________________________

**Follow-up – Medical and obstetric history**

Date: __________________

- History of vaginal bleeding/pain after taking misoprostol: ________________________________
  ___________________________________________________________________________________
  ___________________________________________________________________________________

- Passed tissue or products of conception?  Yes ☐  No ☐
- Current vaginal bleeding?  Yes ☐  No ☐  Amount: ________________________________
- Current pelvic pain or cramping?  Yes ☐  No ☐
  Severity:  Mild ☐  Moderate ☐  Severe ☐
- Does the woman currently feel pregnant?  Yes ☐  No ☐
- Pain medications used: _____________________________________________________________
- Other current medications: _________________________________________________________

**Follow-up – Physical exam**

- Vital signs:
  Blood pressure: ________________________________  Pulse: ________________________________
  Temperature: ________________________________  Respiratory rate: __________________________
- Uterus:
  Size: ________________________________  Tenderness: ________________________________
- Cervical motion tenderness:  Yes ☐  No ☐
- Adnexa:
  Masses: ________________________________  Tenderness: ________________________________
- Speculum exam done?  Yes ☐  No ☐
Specify any abnormal signs
(cervical tears, foreign objects, bleeding visualized, other abnormal sign) __________________________

- Cervix:
  Os: Open □ Closed □

Blood in vaginal vault: Amount/color: __________________________

Mucopurulent discharge: Yes □ No □

__________________________

**Follow-up – Treatment**

- Diagnosis:
  Successful treatment: Yes □ No □

  Any complications: Yes □ No □ If yes, specify: ____________________________

  Abortion still incomplete: Yes □ No □

- Ongoing treatment for incomplete abortion:
  a) Expectant management (re-evaluate in one to two weeks)
  b) Repeat misoprostol and follow-up in one to two weeks
  c) Misoprostol dose and route: ____________________________
  d) MVA
  e) Other: ____________________________
  f) Referral

- For referrals:
  Reason for referral (specify): ____________________________

  Place of referral (specify): ____________________________

  Other notes: ____________________________

**Follow-up – Contraceptive counseling**

- Contraception already being used (previously provided): Yes □ No □

  If no,

  Contraceptive counseling provided: Yes □ No □

  Contraceptive method taken at the end of follow-up visit: ____________________________
### Indications and regimens for misoprostol use

#### Prevention of Postpartum Hemorrhage

<table>
<thead>
<tr>
<th>Misoprostol dose</th>
<th>Route</th>
<th>Timing</th>
</tr>
</thead>
<tbody>
<tr>
<td>600mcg</td>
<td>Oral</td>
<td>To be taken immediately after delivery of newborn. Exclude second fetus (twin) before administration.</td>
</tr>
</tbody>
</table>

Conventional oxytocics should be used over misoprostol, if available.

<table>
<thead>
<tr>
<th>Misoprostol dose</th>
<th>Route</th>
<th>Timing</th>
</tr>
</thead>
<tbody>
<tr>
<td>800mcg</td>
<td>Sublingual</td>
<td>STAT</td>
</tr>
<tr>
<td>OR</td>
<td>Rectal</td>
<td>STAT</td>
</tr>
</tbody>
</table>

#### Treatment of Postpartum Hemorrhage (>500ml Blood Loss)

<table>
<thead>
<tr>
<th>Misoprostol dose</th>
<th>Route</th>
<th>Timing</th>
</tr>
</thead>
<tbody>
<tr>
<td>25mcg</td>
<td>Vaginal</td>
<td>Every 4 hours (up to 6 doses with careful monitoring)</td>
</tr>
</tbody>
</table>

OR

<table>
<thead>
<tr>
<th>Misoprostol dose</th>
<th>Route</th>
<th>Timing</th>
</tr>
</thead>
<tbody>
<tr>
<td>20mcg (dissolve 200mcg tablet in bottle of 200ml clean water. Give 20ml per dose.)</td>
<td>Oral</td>
<td>Every 2 hours (up to 12 doses with careful monitoring). Shake the solution in the bottle well before each dose. Discard bottle after 24 hours.</td>
</tr>
</tbody>
</table>

#### Induction of Labor

Caution with previous cesarean section

<table>
<thead>
<tr>
<th>Misoprostol dose</th>
<th>Route</th>
<th>Timing</th>
</tr>
</thead>
<tbody>
<tr>
<td>25mcg</td>
<td>Vaginal</td>
<td>Every 4 hours (up to 6 doses with careful monitoring)</td>
</tr>
</tbody>
</table>

OR

<table>
<thead>
<tr>
<th>Misoprostol dose</th>
<th>Route</th>
<th>Timing</th>
</tr>
</thead>
<tbody>
<tr>
<td>20mcg (dissolve 200mcg tablet in bottle of 200ml clean water. Give 20ml per dose.)</td>
<td>Oral</td>
<td>Every 2 hours (up to 12 doses with careful monitoring). Shake the solution in the bottle well before each dose. Discard bottle after 24 hours.</td>
</tr>
</tbody>
</table>

#### Incomplete Abortion

<table>
<thead>
<tr>
<th>Misoprostol dose</th>
<th>Route</th>
<th>Timing</th>
</tr>
</thead>
<tbody>
<tr>
<td>600mcg</td>
<td>Oral</td>
<td>Three 200mcg tablets taken at once (single dose)</td>
</tr>
</tbody>
</table>

OR

<table>
<thead>
<tr>
<th>Misoprostol dose</th>
<th>Route</th>
<th>Timing</th>
</tr>
</thead>
<tbody>
<tr>
<td>400mcg</td>
<td>Sublingual</td>
<td>Two 200mcg tablets under the tongue until they dissolve or for 30 minutes; swallow any remaining fragments. (Single dose)</td>
</tr>
</tbody>
</table>

#### Missed Abortion / Anembryonic Gestation

<table>
<thead>
<tr>
<th>Misoprostol dose</th>
<th>Route</th>
<th>Timing</th>
</tr>
</thead>
<tbody>
<tr>
<td>800mcg</td>
<td>Vaginal</td>
<td>Single dose</td>
</tr>
</tbody>
</table>

OR

<table>
<thead>
<tr>
<th>Misoprostol dose</th>
<th>Route</th>
<th>Timing</th>
</tr>
</thead>
<tbody>
<tr>
<td>600mcg</td>
<td>Sublingual</td>
<td>Give every 3 hours for a maximum of 3 doses OR Single dose*</td>
</tr>
</tbody>
</table>

* Sublingual misoprostol 600mcg sublingually every 3 hours for a maximum of 3 doses is one recommended regimen; a single sublingual dose of misoprostol 600mcg may also be used if left to work for 1-2 weeks (unless there is heavy bleeding or infection)


5.5 Preparing women for what to expect

Counseling is an integral part of woman-centered PAC services, and preparing women for what to expect before, during and after treatment with misoprostol is a key part of the clinician’s counseling role. Using simple, non-technical language, health-care staff should help women understand the entire treatment and follow-up process before they take any medications. Any discussion of misoprostol treatment should cover the following topics:

- Choice of misoprostol, vacuum aspiration (if available) or expectant management for incomplete abortion
- Eligibility and effectiveness
- How misoprostol is used
- What the woman is likely to experience
- How long the process typically takes
- Potential side effects and complications
- Warning signs to seek help
- Ensuring access to emergency care
- Contraceptive needs
- Recommended follow-up visit

Drawings often help women understand how medications should be taken. Clinicians may wish to use a pamphlet, card, or handout summarizing the key points. A woman who is unable to read may still find it useful to take written instructions home with her so that a literate relative or friend can read it to her if she has questions.

WHAT IS COUNSELING?

Counseling is “a structured interaction in which a person voluntarily receives emotional support and guidance from a trained person in an environment that is conducive to openly sharing thoughts, feelings and perceptions….effective counseling begins with assessing and addressing each woman’s needs, and includes respectful, woman-centered, two-way communication” (Herrick et al. 2004).
Tool 5F.
Brochures for women

This tool is intended to be given by clinicians to women. It is recommended that facilities pick one route for misoprostol administration that they believe will be most acceptable to communities and easiest to administer. In addition, these materials should be adapted for your local setting.*

Oral administration:

Using misoprostol pills to treat incomplete abortion

**ORAL USE**

**TREATMENT OF INCOMPLETE ABORTION AND MISCARRIAGE WITH MISOPROSTOL PILLS**
If you are having an incomplete abortion, you can be treated safely and effectively with misoprostol pills.

**WHAT WILL HAPPEN WHEN YOU TAKE THE PILLS?**
Misoprostol causes the uterus to contract. You will have some vaginal bleeding and cramping and you may see blood clots.

- **CRAMPING**
- **BLEEDING**

**MANY WOMEN DO NOT HAVE SIDE EFFECTS**
But some women may experience fever, chills, nausea or diarrhea. These should go away on their own in a few hours.

- **DIARRHEA**
- **VOMITING / NAUSEA**
- **FEVER / CHILLS**

* For technical assistance regarding material adaptation, please contact misoforpac@ipas.org
HOW CAN YOU MANAGE THE SIDE EFFECTS?
You can take pain medicines for cramps. Fever medicines are rarely needed. Drinking lots of water and getting rest will also help. Most side effects will disappear on their own in a short time.

WHEN SHOULD YOU SEEK HELP FROM A HEALTH-CARE PROVIDER?
You should seek immediate help if you have:
- Heavy bleeding
- Fever which lasts more than a day or starts any day after the day you take misoprostol
- Constant cramping and pain that does not get better with medication, rest, or heating pad
- The feeling of being very sick

WHAT IS THE BEST CONTRACEPTIVE METHOD FOR ME?
You are able to get pregnant again within a couple of weeks. If you would like contraception, it should be started immediately. You can start most methods at the same time you take your misoprostol tablets.

WHEN SHOULD I COME BACK FOR FOLLOW-UP?
Please come back for a follow-up visit in 1 — 2 weeks to ensure that your treatment was successful.

DATE OF YOUR FOLLOW-UP VISIT:
________________________________________

LOCATION:
________________________________________

PHONE:
________________________________________
Sublingual administration:

Using misoprostol pills to treat incomplete abortion

**SUBLINGUAL USE**

**TREATMENT OF INCOMPLETE ABORTION AND MISCARRIAGE WITH MISOPROSTOL PILLS**
If you are having an incomplete abortion, you can be treated safely and effectively with misoprostol pills.

**WHAT WILL HAPPEN WHEN YOU TAKE THE PILLS?**
Misoprostol causes the uterus to contract. You will have some vaginal bleeding and cramping and you may see blood clots.

**CRAMPING**

**BLEEDING**

**MANY WOMEN DO NOT HAVE SIDE EFFECTS**
But some women may experience fever, chills, nausea or diarrhea. These should go away on their own in a few hours.

**DIARRHEA**

**VOMITING / NAUSEA**

**FEVER / CHILLS**

**HOW TO TAKE MISOPROSTOL PILLS**
Place 2 misoprostol pills (400mcg) under your tongue. Keep pills under your tongue until they melt, or for about 30 minutes, then swallow whatever is left.

00:30
HOW CAN YOU MANAGE THE SIDE EFFECTS?
You can take pain medicines for cramps. Fever medicines are rarely needed. Drinking lots of water and getting rest will also help. Most side effects will disappear on their own in a short time.

WHEN SHOULD YOU SEEK HELP FROM A HEALTH-CARE PROVIDER?
You should seek immediate help if you have:
- Heavy bleeding
- Fever which lasts more than a day or starts any day after the day you take misoprostol
- Constant cramping and pain that does not get better with medication, rest, or heating pad
- The feeling of being very sick

WHAT IS THE BEST CONTRACEPTIVE METHOD FOR ME?
You are able to get pregnant again within a couple of weeks. If you would like contraception, it should be started immediately. You can start most methods at the same time you take your misoprostol tablets.

WHEN SHOULD I COME BACK FOR FOLLOW-UP?
Please come back for a follow-up visit in 1—2 weeks to ensure that your treatment was successful.

DATE OF YOUR FOLLOW-UP VISIT:

LOCATION:

PHONE:
### Expected Treatment Effects of Misoprostol

**(Women will experience these as a result of the products of conception being expelled)**

<table>
<thead>
<tr>
<th>Treatment Effect</th>
<th>Management</th>
</tr>
</thead>
</table>
| Pain/cramping    | - Sitting or lying comfortably   
|                  | - Hot water bottle or heating pad |
|                  | - Give analgesics (ibuprofen or paracetamol/acetaminophen) when the woman is at the clinic so she can take them shortly after taking misoprostol. |

<table>
<thead>
<tr>
<th>Possible Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chills/fever</td>
</tr>
</tbody>
</table>

- Chills are transient; fever is less common and does not necessarily indicate infection. Temperature elevation generally does not last more than a few hours after misoprostol is taken.
- Remind women that fever or chills that persist for longer than 24 hours are not normal and may indicate infection.
- If fever or chills occur on the day that misoprostol is taken, reassure the woman that these are common side effects.

<table>
<thead>
<tr>
<th>Nausea/vomiting</th>
</tr>
</thead>
</table>

- Nausea and vomiting may occur and typically resolve within 2 to 6 hours.
- Reassure the woman that nausea and vomiting are possible side effects.

<table>
<thead>
<tr>
<th>Diarrhea</th>
</tr>
</thead>
</table>

- diarrhea occurs after misoprostol is taken. It usually resolves within a day.
- Remind the woman that diarrhea is sometimes associated with misoprostol use.

### Possible Complications

- Infected abortion.
- This chart lists expected side effects, the most common side effects, possible complications, and related management when using misoprostol for treatment of incomplete abortion.
<table>
<thead>
<tr>
<th>Warning Signs</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Heavy bleeding</strong></td>
<td></td>
</tr>
</tbody>
</table>
| Heavy and/or prolonged bleeding that causes a significant change in hemoglobin is uncommon. Signs that the woman has heavy bleeding and needs to seek help from a clinician include:  
• Soaking two large pads for two hours in a row.  
• Constant heavy bleeding that makes the woman feel sick or weak.  
• Sudden, heavy bleeding after bleeding has slowed or stopped for several days.  
• Weakness, dizziness related to bleeding that starts and stops intermittently for days. | • MVA if bleeding is profuse or prolonged  
• Oral iron supplements or iron-rich diet recommended (but these are not treatments in themselves for heavy bleeding)  
• Fluid resuscitation (oral hydration, intravenous fluids or, rarely, transfusion) if experiencing hemodynamic compromise |
| **Infection** |  |
| Documented endometrial and/or pelvic infection is rare. Signs of infection include some or all of the following fever any day after the day misoprostol is taken, persistent abdominal pain, foul-smelling or purulent cervical/vaginal discharge, flu-like symptoms, feeling generally ill, sometimes accompanied by nausea and vomiting. | • If infection is suspected the woman should be evaluated. If there are signs of sepsis or severe infection the woman should be given immediate surgical evacuation and antibiotic coverage.  
• If the woman is not severely ill, infection is typically treated with oral antibiotics.  
• Severe infections could require hospitalization and IV antibiotics. |
| **Constant pain/cramping** |  |
| Constant severe pain, even on the day misoprostol is taken or pain that persists in days following misoprostol use, despite using medication, rest, a hot water bottle or a heating pad. | • Reassess the woman for treatment failure, unrecognized ectopic pregnancy or any other complications. A thorough assessment is necessary to determine the etiology of the pain. Treat accordingly. |

5.6 Contraceptive services

Contraceptive counseling should be a routine part of postabortion care (see Tool 5H: Contraceptive pocket guide). Clinicians should provide information on the rapid return to fertility and offer appropriate contraceptive counseling and a method of the woman's choice.

- Most contraceptive methods should be provided as soon as possible — usually the same day as misoprostol. Highly effective contraception, such as injectables, contraceptive implants and oral contraceptives can be administered on the same day that misoprostol is given.
- The intrauterine device (IUD) may be inserted at follow-up if the misoprostol treatment was successful.
- If there will be more than a 10-day delay before a woman can start a chosen method, another method, such as condoms, should be provided in the interim.
- Emergency contraception can also be provided to women to take in the event of unprotected intercourse.
- Women should be counseled to delay intercourse until contraception is in place if they want to prevent another pregnancy.

Providing timely counseling can help prevent future unwanted pregnancies. Postabortion contraceptive counseling is also associated with a reduction in maternal and child mortality and prevention of mother-to-child HIV transmission (Curtis et al. 2010). Keep in mind that some women will seek contraceptive services while others will be interested in becoming pregnant again in the near future. **Every woman's situation and contraceptive needs differ.**

When contraceptive counseling and methods are offered after postabortion care, contraceptive acceptance has been shown to be high; this is critical, as women can become pregnant again two to three weeks after taking misoprostol.

Discuss each woman’s reproductive health history with her to understand the causes of the unwanted pregnancy and any previous method failures. Provision of an appropriate contraceptive method will depend on women's needs and preferences as well as local availability.

A range of reproductive health services should be provided. In addition to receiving contraceptive counseling, women should be screened for sexually transmitted infections (STIs) and sexual violence as part of routine PAC services. All women should be advised on the use of condoms to prevent STIs.

**CONTRACEPTIVE COUNSELING FOR POSTABORTION CARE PATIENTS**

Effective postabortion contraception is the best way to prevent future unwanted pregnancies. Unfortunately, it is usually one of the weakest links in postabortion care, and the proportion of women who receive a contraceptive method after postabortion care remains low. Therefore, contraceptive counseling and provision of a method should be priorities in all PAC services. In addition, some women may have experienced an unwanted pregnancy while already using a method; it is very important to address the reasons for method failure, and counsel women accordingly.
The tool below provides information about when various methods of contraception can be started after misoprostol treatment as well as notes for consideration regarding each method.

<table>
<thead>
<tr>
<th>CONTRACEPTIVE METHOD</th>
<th>WHEN METHOD CAN BE OFFERED</th>
<th>NOTES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Condoms</td>
<td>At first visit</td>
<td>Can be used as an interim method; for women who cannot decide about a contraceptive, or who cannot be offered their method of choice immediately after treatment of incomplete abortion.</td>
</tr>
<tr>
<td>Injectables</td>
<td>At first visit</td>
<td>Can be used even if infection is present.</td>
</tr>
<tr>
<td>Oral contraceptives</td>
<td>At first visit</td>
<td>Can be used even if infection is present.</td>
</tr>
<tr>
<td>Intrauterine devices</td>
<td>At follow-up visit</td>
<td>Make sure that treatment is successful; should not be used in the presence of active infection. Provide condoms or other temporary methods until the follow-up visit.</td>
</tr>
<tr>
<td>Implants</td>
<td>At first visit</td>
<td>Can be used even if infection is present.</td>
</tr>
<tr>
<td>Sterilization</td>
<td>At follow-up visit</td>
<td>Provide condoms or other temporary methods until the follow-up visit.</td>
</tr>
<tr>
<td>Diaphragm</td>
<td>At first visit</td>
<td>Consider refitting, depending on gestational age.</td>
</tr>
<tr>
<td>Contraceptive jellies, foams, tablets or films</td>
<td>At first visit</td>
<td>Can be used even if infection is present.</td>
</tr>
<tr>
<td>Skin patches</td>
<td>At first visit</td>
<td>Can be used even if infection is present.</td>
</tr>
<tr>
<td>Vaginal ring</td>
<td>At first visit</td>
<td>Can be used even if infection is present.</td>
</tr>
<tr>
<td>Emergency contraceptive pills</td>
<td>Anytime</td>
<td>Provide emergency contraceptive pills in advance as a back-up method.</td>
</tr>
</tbody>
</table>

For more information, please visit www.ipas.org/medicalabortion
5.7 Follow-up

A follow-up visit should be scheduled one to two weeks following misoprostol administration if feasible; depending on the local circumstances, clinicians also may suggest alternatives to follow-up.

Follow-up visits should cover the following:

- **Treatment outcome**: To determine if treatment was successful, the clinician should ask the woman about her experience and then conduct a physical exam. *Treatment success is defined as complete uterine evacuation and resolution of all symptoms.*

- **Continued incomplete abortion**: If the evacuation process is not yet finished and the woman is clinically stable, she may be offered close observation with expectant management and be re-evaluated in one to two weeks. Alternatively, a repeat dose of misoprostol may be offered (Blum et al. 2007). If the woman is treated with a repeat dose of misoprostol, it is advisable to re-evaluate her in one to two weeks. In the event of infection or clinically significant bleeding, completion through vacuum aspiration should be considered.

- **Contraception**: If the woman wishes to avoid a subsequent pregnancy, ensure that she is comfortable with her contraceptive method, or offer counseling and a method if these have not yet been provided (see Tool 5H: Contraceptive pocket guide).

- **Reproductive health**: Link the woman with other reproductive health services as needed, such as anemia and cervical cancer screening; HIV testing and/or care; referral to a fertility clinic or fertility services; care for sexual and/or domestic violence, STI education, testing and treatment; and assessment of recurrent miscarriage, among others.

5.8 Referrals

Linking misoprostol for postabortion care with reproductive and other health services is important when aspiring to comprehensively address all of women’s health needs. Some services, such as HIV testing or domestic violence counseling, may not be available at the facility providing postabortion care and it may be useful to refer the woman to other facilities that do so.

Referrals to higher-level facilities, such as district hospitals, by lower-level facilities that are using misoprostol for postabortion care should be integrated into existing referral systems. In addition, clinical staff should be aware of the referral facilities and the services they provide (such as surgical services, obstetrics and gynecology, infectious disease services, and others). Tool 5I: Referral Form has two sec-
tions: one that is left with the referring facility and one that is given to the woman to take to the referred facility.
When making a referral, fill out sections A and B; section A stays in the initial facility and section B is given to the woman to take to the referral site.

### POST ABORTION CARE REFERRAL FORM

#### SECTION A: STAYS AT THE CLINIC INITIATING THE REFERRAL

| Patient: |  |
| Contact: |  |
| Facility name where referral was made: |  |
| Date of referral: _____ / _____ / _____ |  |
| DD | MM | YY |
| ☐ Emergency referral | ☐ Non-emergency referral |
|  |
| Reason for referral: |  |
| ☐ Complicated case (heavy bleeding, uterine perforation, signs of sepsis or other reason) |  |
| ☐ Pregnancy beyond 12 weeks uterine size, or problems determining uterine size |  |
| ☐ Service requested by the patient available in the facility |  |
| ☐ Patient’s preference |  |
| ☐ Other (please specify): |  |

#### SECTION B: WOMAN TAKES TO REFERRAL CLINIC (attach to copy of patient chart)

| Patient: |  |
| Contact: |  |
| Facility name where referral was made: |  |
| Date of referral: _____ / _____ / _____ |  |
| DD | MM | YY |
| ☐ Emergency referral | ☐ Non-emergency referral |
|  |
| Reason for referral: |  |
| ☐ Complicated case (heavy bleeding, uterine perforation, signs of sepsis or other reason) |  |
| ☐ Pregnancy beyond 12 weeks uterine size, or problems determining uterine size |  |
| ☐ Service requested by the patient available in the facility |  |
| ☐ Patient’s preference |  |
| ☐ Other (please specify): |  |

Treatment initiated at referring facility (antibiotics, cultures, lab results, other):  

__________________________________________________________________________  

__________________________________________________________________________  

__________________________________________________________________________  

---

5.9 Learning from adverse events

Adverse events (AEs) are complications that a woman suffers during or immediately after her treatment that need to be investigated further. Investigation focuses on whether the events were treatment-related and whether and how they could have been prevented. A serious adverse event (SAE) is one that is life-threatening, results in permanent impairment of body function or permanent damage to body structure, or necessitates medical or surgical intervention to preclude permanent impairment (see Tool 5J: Serious Adverse Event form). Although incomplete abortion inherently leads to some complications, most are easily treated; serious complications are rare in routine postabortion care.

Adverse events may result from patient factors, human error or institutional problems, but usually occur after multiple factors come together during a single event.

When an adverse event has occurred, the first step is to care for the woman involved, and also hold an initial conversation with the patient and/or her family. In this conversation, you should state very briefly what is known about the complication, express regret that the woman experienced a complication, and provide assurance that the event is being taken seriously and will be thoroughly analyzed.

Most AEs involve system failure. Even if an individual clinician demonstrates lack of judgment or inadequate skill, the system likely has not provided the training, monitoring or mentoring needed to support quality of care. In a just culture, the goal is therefore to support rather than blame the involved staff, while learning from the event. Solutions that focus on systems improvement rather than individuals are more likely to lead to AE reporting, prevention and improved outcomes. Moreover, involving the entire team in case studies of AEs can help staff understand the cascade of events that led to the complication and whether and how it could have been averted. However, some complications cannot be foreseen or averted.

All health services create opportunities to learn invaluable lessons, especially when the services are new. It is important, then, to provide opportunities for staff to debrief after implementation of services offering misoprostol for postabortion care has begun, so that staff can learn from case studies, review data, monitor trends, raise questions and address areas of confusion. If a system exists that allows local and national health services to access this information, these entities can use the information to understand trends, identify needs and support local services.
## Serious adverse event form

*Use this form to document all adverse events occurring during postabortion care (PAC). Contact local authorities if there is a cohesive monitoring system in place or if you are required to do so, and provide the following information within 24 hours of learning of a new serious adverse event or if you are updating information previously reported on this form. In the spirit of learning for improvement, review this information as a team to determine if anything can be changed to improve quality of care and/or outcomes.*

<table>
<thead>
<tr>
<th>Question</th>
<th>Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Patient information</td>
<td>Name: ___________________________</td>
</tr>
<tr>
<td></td>
<td>Age: ___________________________</td>
</tr>
<tr>
<td>2. Serious Adverse Event</td>
<td>☐ Severe allergic reaction to drug</td>
</tr>
<tr>
<td></td>
<td>☐ Shock</td>
</tr>
<tr>
<td></td>
<td>☐ Profuse bleeding leading to the need for transfusion</td>
</tr>
<tr>
<td></td>
<td>☐ Ectopic pregnancy unrecognized at time of procedure or when misoprostol</td>
</tr>
<tr>
<td></td>
<td>was given</td>
</tr>
<tr>
<td></td>
<td>☐ Prolonged or difficult surgical procedure (for example, uterine perforation)</td>
</tr>
<tr>
<td></td>
<td>☐ Signs of infection requiring hospitalization and IV antibiotic treatment</td>
</tr>
<tr>
<td></td>
<td>Describe signs: ________________________________________________________</td>
</tr>
<tr>
<td></td>
<td>☐ Other diagnosis: _____________________________________________________</td>
</tr>
<tr>
<td>3. Outcome of Serious Adverse Event Event</td>
<td>☐ Death</td>
</tr>
<tr>
<td></td>
<td>☐ Life-threatening experience</td>
</tr>
<tr>
<td></td>
<td>☐ New or prolonged hospitalization</td>
</tr>
<tr>
<td></td>
<td>☐ Persistent/significant disability or incapacity</td>
</tr>
<tr>
<td></td>
<td>☐ Uterine perforation</td>
</tr>
<tr>
<td></td>
<td>Surgical repair required? No ☐ Yes ☐</td>
</tr>
<tr>
<td></td>
<td>☐ Other</td>
</tr>
<tr>
<td></td>
<td>Specify: ___________________________</td>
</tr>
<tr>
<td>4. Resolution</td>
<td>☐ Continuing</td>
</tr>
<tr>
<td></td>
<td>☐ Resolved: _____ / _____ / ____                  DD MM YY</td>
</tr>
<tr>
<td></td>
<td>☐ Death</td>
</tr>
</tbody>
</table>

---

22. A **serious adverse event** (SAE) is one that is life-threatening, results in permanent impairment of body function or permanent damage to body structure, or necessitates medical or surgical intervention to preclude permanent impairment.
<table>
<thead>
<tr>
<th>Question</th>
<th>Response</th>
</tr>
</thead>
</table>
| 5. Treatment (mark all that apply) | □ None  
□ Blood transfusion  
□ New/prolonged hospitalization  
□ Uterine evacuation  
□ IV/antibiotics  
□ Surgery, describe: ____________________________________________

___________________________________________________________

□ Patient referred (specify where)  
If this woman is returning for evacuation, please indicate her date of initial visit: _____ / _____ / _____

□ Medications (including misoprostol)  
List date given, name of drug, dose, and route: ____________________________________________

___________________________________________________________

If misoprostol is given more than one time, list drug dose and date for each administration:

___________________________________________________________

□ Other treatment  
Specify: ____________________________________________

6. Completed by:  
Name: ____________________________________________

Facility: ____________________________________________

Phone #: ____________________________________________
TEAM MEETING/CASE REVIEW

To be completed with all relevant facility staff, conducted in the spirit of learning for improvement.

a. What happened? ⇒ Summarize the precise chronology of the event and any associated unsafe actions or omissions. 

______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________


______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________

c. What can be changed to prevent similar events in the future? 

______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
5.10 Additional resources


6.1 Introduction

Sites and programs should begin to develop a plan for ongoing monitoring of service delivery and quality at the earliest stages of planning for the introduction or integration of misoprostol for the treatment of incomplete abortion. It is important to decide on a system for continual monitoring and supportive supervision while services are being put into place. This allows facilities to collect all necessary data from the beginning and to compare data to the baseline results of the environmental and facility assessments. Choose monitoring measurements that are directly in line with the specific objectives designed for the introduction or integration of misoprostol, and select indicators that will meaningfully inform service improvements.

Module 6 provides you with a framework and tools for monitoring the quality of postabortion care (PAC) services to ensure that minimum standards of quality are met and to identify ways to improve services.

6.2 Monitoring to assess and improve quality of services

It is important to determine if specific quality objectives are being met. Monitoring is a system of information gathering and regular assessment of how a program is functioning. Monitoring is an ongoing process to gather and analyze information in a systematic, routine way. Ideally, monitoring data lead to insights about how to improve implementation so that women receive high quality services and health-care workers have the resources they need to provide high quality care.

6.3 Six monitoring areas of misoprostol use in PAC services

For the purposes of this toolkit, there are six aspects of service delivery and use that should be monitored:

1. Resources: Are more inputs needed for the misoprostol for postabortion care program to run efficiently? Inputs include trained clinicians and misoprostol supply (please refer to Tool 3A: Minimum requirements for treatment of incomplete abortion with misoprostol).
2. **Service utilization**: What services are being provided and to how many women over what period of time?

3. **Clinical services**: Are services provided per the medical and clinical protocols? These include using appropriate technologies for treatment of incomplete abortion, using misoprostol correctly, and consistently providing women with accurate information, including routine contraceptive counseling and method provision.

4. **Complications and referral**: How many women are experiencing post-procedure complications? How many women are being referred to other facilities?

5. **Recordkeeping and management of services**: Are services properly documented? Are services being run efficiently?

6. **Overall quality**: What are clinicians’ perspectives on quality of services? What challenges do they face? What are women’s perceptions on quality of services? How do women think that services might be improved?

### 6.4 Developing a monitoring plan to ensure high quality of services

Creating a quality monitoring plan includes determining the aspects of services to be monitored, deciding on the methods and tools that will be used to gather information, establishing benchmarks and standards of quality, and determining roles and responsibilities for implementing the monitoring plan.

Monitoring plans will vary by level due to resources available and the monitoring objectives themselves. **Tool 6A: Indicators by facility level** provides guidance into what should be included in monitoring plans at the community, health center, hospital, and district/regional health system levels. All of the indicators correspond to one of the six monitoring areas of misoprostol use in PAC services listed in section 6.3.

In general, health centers and larger entities should focus on creating monitoring systems that collect information to improve quality. Larger facilities and health systems might also include measurements of the impact of their services in the community, such as reduced hospitalizations for abortion-related complications. In addition, all facilities should ensure that they are meeting government or donor reporting requirements.

Use **Tool 6A** when designing your monitoring plan to decide which indicators to include and how to collect them. The toolkit also provides templates for the information sources listed in **Tool 6A**.

---

**AN IMPORTANT MESSAGE ABOUT MONITORING**

This module provides a framework for developing a monitoring plan for misoprostol use in postabortion care. If a monitoring system already exists in your health facility, use the information in this module to integrate monitoring of misoprostol services into your existing system. Whether you are adapting an existing monitoring plan or creating a new one, be sure to fulfill the reporting requirements as indicated by your facility, district, regional, and/or national guidelines.
For example, you can use Tool 6B: Service delivery logbook to collect the data needed to measure the number of incomplete abortion cases treated using each method, the percentage of women receiving the correct dose and route of misoprostol, and the percentage of women receiving a contraceptive method. This information can be summarized monthly for monitoring purposes using Tool 6C: Monthly service report. You can also revise your existing logbook to include PAC data. Information for other indicators may come from activities conducted during supervisory visits (see Tool 6D: Supervisory and performance quality improvement checklist), by assessments of patient satisfaction (see Tool 6E: Patient satisfaction rapid assessment), or from other information such as patient records.
As you create your monitoring plan, identify the indicators for which you may already be collecting data as part of your health management information system (MIS). Next, identify indicators you need to collect for your misoprostol for postabortion care program. The indicators in Tool 6A are based on the six monitoring areas of misoprostol for use in PNC services described in section 6.3. Think through the resources needed to collect additional data and weigh the benefits of the information relative to the cost of collecting it. Data should be collected on a routine basis (monthly or quarterly).

### Level 1: Community (Provider trained in referral and contraceptive provision only)
- **Notes:**
  - Consider the specific characteristics of your provider population when selecting indicators.
- **Information Source(s):**
  - Review of patient records
- **Indicators:**
  - Number of women referred to other facilities because of complications by type of complication
  - Number of women who received misoprostol and developed complications and referred
  - Percentage of cases receiving correct dosage and route of misoprostol
  - Percentage of women provided with contraceptive method
  - Percentage of cases receiving follow-up
  - Number of incomplete abortion cases treated with misoprostol
  - Number of incomplete abortion cases
  - Percentage of women referred to other facilities because of complications
  - Percentage of women receiving postabortion care

### Level 2: Health center (Primary health clinics, family health centers, etc.)
- **Notes:**
  - Consider using Tool 6B: Service delivery logbook and supply ledgers to regularly collect basic information on the resources needed (such as number of trained clinicians and misoprostol stock) and services provided (such as the number of women who received misoprostol and the number of patients seen).
- **Information Source(s):**
  - Review of patient records
  - Tools (6C: Monthly service report; 6D: Supervisory and performance quality improvement checklist; 6E: Patient satisfaction rapid assessment)
- **Indicators:**
  - Number of clinicians trained in misoprostol for treatment of incomplete abortion
  - Misoprostol stock at the facility
  - Number of incomplete abortion cases
  - Number of incomplete abortion cases treated with misoprostol
  - Rate of follow-up
  - Percentage of cases receiving correct dosage and route of misoprostol
  - Percentage of women who received misoprostol and developed complications
  - Percentage of women referred to other facilities because of complications

### Level 3: Facility (Health center)
- **Notes:**
  - Consider using Tool 6B: Service delivery logbook and supply ledgers to regularly collect basic information on the resources needed (such as number of trained clinicians and misoprostol stock) and services provided (such as the number of women who received misoprostol and the number of patients seen).
  - Consider using Tool 6E: Patient satisfaction rapid assessment if appropriate.
- **Information Source(s):**
  - Review of patient records
  - Tools (6C: Monthly service report; 6D: Supervisory and performance quality improvement checklist; 6E: Patient satisfaction rapid assessment)
- **Indicators:**
  - Number of clinicians trained in misoprostol for treatment of incomplete abortion
  - Misoprostol stock at the facility
  - Number of incomplete abortion cases treated with misoprostol
  - Rate of follow-up
  - Percentage of women who received misoprostol and developed complications
  - Percentage of women referred to other facilities because of complications
<table>
<thead>
<tr>
<th>Hospital (district, regional, or national)</th>
<th>Health center-level indicators plus: Complications and referral</th>
<th>No additional notes.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall quality</td>
<td>• Percent of patients who answer “yes” to eight or more questions in Tool 6E: Patient satisfaction rapid assessment</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Review of patient records (see Tool 5D: Patient chart)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Tool 5J: Serious Adverse Event form</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Tool 6B: Service delivery logbook</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Tool 6C: Monthly service report</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Number of abortion-related deaths per reporting period and associated type of complication</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Number of hospitalizations for abortion-related complications per reporting period</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Number of referrals received from other health facilities for complications of incomplete abortion per reporting period</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Facilities with misoprostol in stock as percentage of facilities that treat incomplete abortion</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Number of clinicians trained in misoprostol for postabortion care</td>
<td></td>
</tr>
<tr>
<td>Resources</td>
<td>• Proportion of facilities that have recently provided treatment of abortion complications</td>
<td></td>
</tr>
<tr>
<td>Service utilization</td>
<td>• Number of women treated for incomplete abortion across all facilities and by type of facility</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Number of deaths from abortion complications</td>
<td></td>
</tr>
<tr>
<td>Recordkeeping and management of services</td>
<td>• Distribution of methods used for incomplete abortion across all facilities, and by type of facility</td>
<td></td>
</tr>
</tbody>
</table>

| District /Regional health system         | Resources                                                     | No additional notes. |
6.5 Gathering information for monitoring

Programs can use many methods to gather information for monitoring purposes, including document review, observation, and interviews. Basic data collection strategies include:

- Compiling program data (such as supply ledgers, patient records, logbooks) into a monthly summary report
- Conducting supportive supervision visits on a less frequent basis (such as quarterly)
- Conducting exit interviews with patients

Compiling program data

Clinicians and administrators routinely keep records of services provided, using logbooks, clinical records, and supply ledgers. On a routine basis (for example, monthly), these can be used as sources of information for measuring resources and service utilization. For example, using information collected in Tool 6B: Service delivery logbook, you can fill out Tool 6C: Monthly service report. After you fill out this report each month, you will have a summary, disaggregated by method of treatment of incomplete abortion, of:

- number of women treated for incomplete abortion
- number of women discharged with a contraceptive method
- number of women who returned for a follow-up visit
- number of women with complications
- number of women referred

This information is useful to review on an ongoing basis to better understand your case flow as well as the percentage of women treated for incomplete abortion who are provided with contraception.

Conducting supportive supervision visits

It is important – if feasible – to provide supportive supervision and assess service quality on a regular basis (see Tool 6D: Supervisory and performance quality improvement checklist). Checklists can help maintain a focus on key service delivery and quality areas, aid in collecting information in a systematic manner, and establish and assess criteria or standards. The checklist provided in Tool 6D may include more items than are necessary to measure the indicators you have chosen for your monitoring plan; remove any questions that are not relevant to reduce the burden on interviewees, supervisors, and clinicians. Supportive supervision visits also typically include opportunities for staff to debrief about the service (especially when it is new) and to share observations about what has been successful.

---

versus problematic and suggest solutions.

**Conducting exit interviews with patients**

When examining quality of services, it is important to learn how women feel about the services they have received. Tool 6E: Patient satisfaction rapid assessment is a quick way to gauge patient satisfaction with services. Depending on a woman’s level of literacy, the assessment can be completed by the woman herself or by someone reading the form to her. If someone assists the woman in completing the assessment form, it must be done by someone who did not provide services to the woman on either her initial or follow-up visit. It is advisable to pay particular attention to the needs of special populations, including youth.

Those interested in collecting more in-depth information on patient perspectives of services should use a more detailed questionnaire. The Additional Resources section at the end of this module suggests information and tools that can generate more comprehensive patient satisfaction assessments.
Facilities often keep a patient registry that summarizes the treatment received. The Service delivery logbook provides a quick and efficient way for facilities to keep track of postabortion care services. This tool provides a snapshot of service utilization that facilities should monitor and review on a regular (monthly) basis. This tool is intended to be adapted to a facility’s needs and local reporting requirements. The logbook can be used for initial visits or follow-up services.

Continued on next page ...
<table>
<thead>
<tr>
<th>Date (d/m/y)</th>
<th>Patient ID</th>
<th>Age</th>
<th>Uterine size (weeks)</th>
<th>Clinician type</th>
<th>ID/Name</th>
<th>Dosage</th>
<th>Route</th>
<th>Contraceptive method</th>
<th>Follow-up visit</th>
<th>Complications</th>
<th>Referral</th>
<th>Comments &amp; quality review</th>
</tr>
</thead>
<tbody>
<tr>
<td>23/3/10</td>
<td>12345</td>
<td>26</td>
<td>10</td>
<td>Nurse-midwife</td>
<td>Abcd</td>
<td>600mcg</td>
<td>X</td>
<td>Yes/No (Indicate type, for example: pills, condoms, IUD.)</td>
<td>Yes/No (Indicate if this is a follow-up visit.)</td>
<td>Yes/No (Indicate type)</td>
<td>Yes/No (If patient was referred, indicate site and reason for referral.)</td>
<td>Patient returned one week after treatment with heavy bleeding</td>
</tr>
<tr>
<td>24/3/10</td>
<td>11259</td>
<td>19</td>
<td>9</td>
<td>Nurse-midwife</td>
<td>Hijklmno</td>
<td>600mcg</td>
<td>X</td>
<td>Yes: IUD</td>
<td>Yes</td>
<td>Yes</td>
<td>None</td>
<td>Yes- For IUD at local hospital</td>
</tr>
<tr>
<td>24/3/10</td>
<td>14798</td>
<td>35</td>
<td>9</td>
<td>Physician</td>
<td>Pqrstuv</td>
<td></td>
<td>X</td>
<td>Yes: injectable</td>
<td>Yes</td>
<td>None</td>
<td>N/A</td>
<td>Two weeks since successful treatment with misoprostol.</td>
</tr>
</tbody>
</table>

Examples: 23/3/10 12345 26 10 Nurse-midwife Abcd 600mcg X None provided No Patient returned one week after treatment with heavy bleeding N/A Referred to us by pharmacist with bleeding and cramping.

24/3/10 11259 19 9 Nurse-midwife Hijklmno 600mcg X Yes: IUD Yes None Yes- For IUD at local hospital

24/3/10 14798 35 9 Physician Pqrstuv X Yes: injectable Yes None N/A Two weeks since successful treatment with MVA.
Tool 6C.
Monthly service report

As part of the monitoring plan, a small number of key indicators should be assessed on a monthly basis, namely resources needed (supplies) and service utilization (including the number of patients, method of treatment used for incomplete abortion, and post-treatment contraceptive provision). Collect this information from the relevant and available registries, records (such as Tool 6B: Service delivery logbook), and supply logs (such as supply ledgers).

Name of health institution: __________________________________________________________

District: ________________________________________________________________________

Year and month: __________________________________________________________________

Completed by: ____________________________________________________________________

Service utilization

<table>
<thead>
<tr>
<th>Method for treatment of incomplete abortion</th>
<th>Total number treated</th>
<th>Number discharged with a contraceptive method</th>
<th>Number returned for a follow-up visit</th>
<th>Number with complications</th>
<th>Number referred</th>
</tr>
</thead>
<tbody>
<tr>
<td>Misoprostol</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MVA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Expectant management</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes: ___________________________________________________________________________

________________________________________________________________________________
Supportive supervision visits should be scheduled on an ongoing basis (for example, quarterly). Adapt this checklist to meet the needs of your supervision and monitoring plan.

Name of health institution: ____________________________________________________________

Location: _________________________________________________________________________

Period under review: __________ to __________ Date of visit: _____________________________

Completed by: _____________________________________________________________________

Recommended steps:

- Conduct a review of 10 patient records chosen at random. By reviewing individual patient records, you can gather information on adherence to medical protocol, proper documentation of services, rate of follow-up attendance, and other issues. Confirm that clinicians provided the correct dose and route to each patient receiving misoprostol as well as appropriate pain management.

- Observe 10 clinician-patient interactions, from the initial contact until the patient is discharged. This will allow you to assess client flow, informed consent procedures, patient privacy, as well as patient-provider communication and staff attitudes and perceptions. Discuss results of observations with clinicians.

- Examine and discuss with clinicians the quality of counseling and information given to women about the misoprostol treatment procedure and postabortion contraception, the systems for post-treatment contraception and referral for other services. Discuss provision of care with clinicians and other staff. Here are some issues to explore with staff:
  - Do they feel comfortable providing misoprostol for treatment of incomplete abortion?
  - Is there additional information, training, or support they need to feel more comfortable?
  - How do they feel about the women they are treating?
  - Do they have any negative attitudes about women, or particular groups of women (such as HIV-positive, young, or unmarried women), coming for treatment?
  - Do they have any negative attitudes toward providing the service?
  - What would enable them to provide better quality services?
  - Do they feel supported by other staff and supervisors to provide quality services?
  - Are they able to make suggestions and positive changes?

- If possible, assess patients’ views of service quality by asking them to participate in a quick survey. (See Tool 6E: Patient satisfaction rapid assessment at the end of this module for an example.)

- Complete the supervisory checklist and discuss the results with your health-care team and managers.

# Supervisory and performance quality improvement checklist

## Recordkeeping and management of services

Staff are using the recordkeeping and reporting systems correctly, including:

- Patient forms filled out correctly
- Logbook filled out consistently
- Supply ledger filled out consistently

Internal supervision system exists and is functioning

*Efficient patient flow (minimal waiting time before and after treatment)*

**Average amount of time from arrival to procedure:**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Hours services are available:**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Resources *(Indicate if items are available and/or stocked. If they are not, state the reason and exactly what product or item is missing.)*

**Infrastructure, furniture and equipment**

- Counseling and examination room(s)
- Toilet facilities
- Clean water supply

**Equipment and supplies**

- Supplies for pelvic and bimanual exam, including speculum, gloves, etc.
- Disinfection supplies for instruments and gloves

**Drugs and contraceptive supplies**

- Misoprostol
- Analgesics (ibuprofen, paracetamol) and antipyretics
- Contraceptive supplies
<table>
<thead>
<tr>
<th>Supervisory and performance quality improvement checklist</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Yes</strong></td>
</tr>
<tr>
<td>---------------------------------------------------------</td>
</tr>
<tr>
<td>Emergency treatment supplies (for referral health facilities)</td>
</tr>
<tr>
<td>- Emergency resuscitation materials and drugs (including IV lines and fluids, blood transfusion/blood)</td>
</tr>
<tr>
<td>- Manual vacuum aspiration (MVA) equipment</td>
</tr>
<tr>
<td>- Other evacuation equipment if MVA is not available</td>
</tr>
<tr>
<td>There is an adequate supply of misoprostol pills throughout the month.</td>
</tr>
</tbody>
</table>

**Staffing**

All staff are trained on misoprostol medical and programmatic protocols.

Number of clinicians trained to provide misoprostol for treatment of incomplete abortion: ________

Is this number adequate to meet the patient load? Yes ☐ No ☐

**Patient satisfaction**

Patients seem satisfied with services. (see Tool 6E: Patient satisfaction rapid assessment)

Patients have complaints.

Describe in additional comments section at the end

**Contraceptive service provision**

What types of contraceptive methods are available? (☑ all that apply)

- Oral pills
- Male condoms
- Female condoms
- Spermicides
- Implants
- Injectables
- IUDs
- Male sterilization
- Female sterilization
- Other: __________________________

Most popular method: __________________________ Next most popular: __________________________
<table>
<thead>
<tr>
<th>SUPERVISORY CHECKLIST</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Yes</strong></td>
</tr>
<tr>
<td>Adequate supply of contraceptives, including all methods that should be available at this clinic</td>
</tr>
<tr>
<td>Obstacles to providing contraceptive services: (✓ all that apply)</td>
</tr>
<tr>
<td>☐ Staff not adequately trained in contraceptive services.</td>
</tr>
<tr>
<td>☐ Staff do not have time to counsel.</td>
</tr>
<tr>
<td>☐ Contraceptive methods are not available at all times.</td>
</tr>
<tr>
<td>☐ Contraceptive counseling and stock of methods are in different locations [for resupply methods, not for IUD and/or sterilization].</td>
</tr>
<tr>
<td>☐ Method(s) not available where services are provided. (list) ____________________________</td>
</tr>
<tr>
<td>☐ Contraceptive board not displayed.</td>
</tr>
<tr>
<td>☐ Patients not interested in discussing contraceptive services.</td>
</tr>
<tr>
<td>☐ Method(s) ordered but not received. (list) ____________________________</td>
</tr>
<tr>
<td>☐ Method(s) not approved for use by facility. (list) ____________________________</td>
</tr>
</tbody>
</table>

Major observations and additional comments: ____________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________
Patient satisfaction rapid assessment

This tool can be used to help you determine patient satisfaction with misoprostol for postabortion care services, as well as provide insights into how services are being provided in your facility. Make sure you explain to the woman: the purpose of the assessment; that all responses to the assessment are confidential; and that participation will have no effect on care received now or in the future. In addition, make sure the woman understands that she does not have to participate. Allow the woman to complete the form in a private space, either by herself or with the assistance of someone who did not provide her services.

<table>
<thead>
<tr>
<th>Name of health facility: ___________________________</th>
<th>Date: _____ / _____ / _____</th>
</tr>
</thead>
</table>

Please read each of the ten items below, and place a check mark (✓) in the appropriate column.

<table>
<thead>
<tr>
<th></th>
<th>Yes</th>
<th>No</th>
<th>Not sure</th>
<th>N/A</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Was your clinician able to attend to you quickly?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 Did the clinician explain what to expect?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 Did you get enough information to meet your needs?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 Did you feel comfortable discussing your health needs with your clinician?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 Do you feel you had enough time with your clinician to discuss everything you needed?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 Do you feel your clinician treated you with respect?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7 If MVA and misoprostol were both available at the facility, were you able to choose the method you wanted for your treatment?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 If there was a cost involved in your treatment, did you feel that the cost was appropriate (not too expensive)?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9 Would you recommend services to a friend who needed care?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 Overall, are you satisfied with the services you received today?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Comments and additional recommendations for service improvement

Thank you for your participation.
Tool 6E. Patient satisfaction rapid assessment
6.6 Compiling and synthesizing monitoring data

The objective of data monitoring activities is to identify the service areas that are most in need of attention so that you can study them more thoroughly and take action. Compiling and reviewing the findings of the monitoring process presents an opportunity to openly discuss the strengths and weaknesses of the facility, conceive and implement a plan of action for improvement, and assess progress in improving care.

You should compile and synthesize the data collected during the information-gathering process so that each member of the monitoring team can review them. The team should then identify problem areas and issues of concern, as well as areas of strength and competency, so as to identify potential solutions. For example, the underlying causes of deficient counseling services might be identified as a lack of staff training in counseling and a patient intake process that leaves insufficient time for counseling. The group might also identify causes that are more pervasive, for instance, an underlying belief that counseling is not an important part of the service delivery process.

Often, a team may find that surface problems and their underlying causes are interrelated. This is important because the monitoring team may be able to develop solutions aimed at correcting several problems at once. The team must decide which problems are high priority and will be included in the improvement plan.

6.7 Developing a workplan for continuous quality improvement

After identifying and assessing problem areas, the monitoring team can develop an action plan to try to resolve the problems and improve the quality of PAC services. An action plan can help improve service provision, especially if the plan prioritizes issues, develops solutions, and matches solutions to available resources.

The team should carefully discuss a range of approaches to each problem before reaching a decision about which solution is most feasible. It is helpful to list alternate solutions as potential future options, in case the initial solution does not meet expectations.

After implementation of the action plan, it is important to carry out continuous monitoring to determine: 1) if the action plan was implemented correctly, and 2) whether the corrective action actually improved the problem area. If the problem persists (assuming the corrective action was implemented), this means that the team did not correctly identify the root cause of the problem, or that the corrective action was not on target to solve the problem. In this case, the root

POSSIBLE SERVICE DELIVERY IMPROVEMENT SOLUTIONS

- On-the-job training for staff
- Reorganization of clinic services
- Changes to clinic hours of operation
- Changes to supplies procurement and storage systems
- Strengthening referral systems
cause must be reassessed and a new action plan developed and monitored. This process is called continuous quality improvement.

For example, if only 50 percent of women completing Tool 6E: Patient satisfaction rapid assessment at a given facility answer “yes” to eight or more questions, the monitoring team can develop a strategy to improve the overall quality of care that is being provided. As another example, if the findings of Tool 6D: Supervisory and performance quality improvement checklist reveal that patient forms are not being filled out correctly, the monitoring team can discuss this with the health-care team and work on finding a solution.
6.8 Additional resources


Contact information

Thank you for using Misoprostol use in postabortion care: A service delivery toolkit. If you need additional information, technical assistance in implementing these services, or would like to provide our team with feedback, please contact us at the following email addresses: misoforpac@ipas.org or info@vsinnovations.org.
References by Module

Overview


Module 1: Introduction


Faundes, Anibal. 2005. Use of misoprostol in obstetrics and gynecology. FLASOG.


World Health Organization. 2007. Unsafe abortion: Global and


Module 2: Planning for service delivery


Module 3: Assessing your facility


Module 4: Creating community linkages


Module 5: Delivering clinical services


Diop, Ayisha, Sheila Raghavan, Jean-Pierre Rakotovao, Rodica Comendant, Paul D. Blumenthal and Beverly Winikoff. 2009. Compa-


Faundes, Anibae. 2005. Use of misoprostol use in obstetrics and gynecology. FLASOG


Weeks, Andrew, Godfrey Alia, Jennifer Blum, Beverly Winikoff, Paul


**Module 6: Ensuring high quality services**

ANNEX 1: Clinical assessment reference guide: Overview of misoprostol for the management of incomplete abortion

A. Introduction

Incomplete abortion occurs when a pregnant woman presents with vaginal bleeding, cramping, and an open cervix. She may also be passing products of conception (POC). Misoprostol provides a safe and effective way to treat women experiencing incomplete abortion (Chung et al. 1995, Clark et al. 2007, Diop et al. 2009, Gynuity Health Projects 2009, Rizzi 2007, Shwekerela et al. 2007). Studies have reported high satisfaction with misoprostol among women (Bique et al. 2007, Dao et al. 2007, Shwekerela et al. 2007, Weeks et al. 2005), and a preference for medical versus surgical treatment (Dabash et al. 2010, Diop et al. 2009). Misoprostol has several notable advantages, including ease of use and low cost (WHO 2003, You and Chung 2005). Regarding ease of use, the drug can be administered by clinicians with minimal training via several routes, can be used in remote areas without need of specialized equipment, can be self-administered, avoids iatrogenic injury, and reduces risk of pelvic infection. Misoprostol requires no refrigeration or special transport or storage conditions, though some manufacturers recommend protecting the product from heat and humidity (POPHI 2008).

B. Misoprostol uses, administration and mode of action

Misoprostol is a prostaglandin E1 analogue. When taken during pregnancy, it causes the cervix to soften and the uterus to contract. Misoprostol has several uses in obstetrics and gynecology, which include treatment of incomplete abortion and miscarriage; treatment of missed abortion (including intrauterine fetal death); labor induction; prevention and treatment of postpartum hemorrhage; cervical priming; and pregnancy termination (FLASOG 2007, Goldberg et al. 2001, Weeks and Faundes 2007, WHO 2003). Because the uterus becomes much more sensitive to the effects of misoprostol as pregnancy advances, doses of misoprostol for labor induction are much lower than doses for first-trimester postabortion care treatment.

Routes of misoprostol administration include oral, sublingual, buccal, vaginal and rectal. Sublingual and oral routes have the quickest onset of action (Tang et al. 2007). For the treatment of incomplete abortion, misoprostol 400mcg sublingually and misoprostol 600mcg orally have similar safety and effectiveness profiles when used with uterine size less than or equal to 12 weeks LMP (last menstrual period) (Diop et al. 2009, Gynuity Health Projects 2009).

---


**Misoprostol for the treatment of missed abortion and anembryonic gestation**

Although this toolkit focuses on the indication of misoprostol for the treatment of incomplete abortion, misoprostol, as noted, can also be used for the treatment of missed abortion and anembryonic gestation. Because both types of early pregnancy loss involve little to no bleeding and a closed cervix, misoprostol treatment is not as effective for these indications as it is for incomplete abortion. The dosage for missed abortion and anembryonic gestation is misoprostol 800mcg vaginally or misoprostol 600mcg sublingually every three hours for a maximum of three doses. Treatment of missed abortion with sublingual misoprostol has not been widely studied. A single sublingual dose of misoprostol 600mcg may also be effective. Reported success rates for misoprostol treatment of missed abortion vary widely. For more detailed information about the reported use of misoprostol treatment for missed abortion, see Gynuity Health Projects’ introductory guidebook, *Misoprostol for treatment of incomplete abortion*.

**C. Regimens and efficacy of misoprostol treatment for incomplete abortion**

For the purposes of standardization and to avoid confusion, it is advisable that local experts and authorities select one misoprostol regimen to use in their country. For more detailed information on misoprostol administration and dosing, see Tool 5E: Dosage card.

<table>
<thead>
<tr>
<th>Uterine Size</th>
<th>Misoprostol dose</th>
<th>Route</th>
<th>Timing</th>
<th>Success</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>400mcg</td>
<td>Sublingual</td>
<td>Two 200mcg tablets under the tongue for 30 minutes, then swallow the remaining pill fragments.</td>
<td>95-98 percent</td>
<td>(Dabash et al. 2010, Diop et al. 2009)</td>
<td></td>
</tr>
</tbody>
</table>

---

3 Success is defined here as complete uterine evacuation without further intervention with vacuum aspiration or curettage.
D. Eligibility

Misoprostol may be used to treat incomplete abortion for eligible women.

**Conditions for eligibility:**

Women with any of the following conditions are eligible for misoprostol:

- Open cervical os
- Vaginal bleeding or history of vaginal bleeding during this pregnancy
- Uterine size at or under 12 weeks LMP

**Conditions for ineligibility**

Women with any of the following conditions are not eligible for misoprostol:

- Known allergy to misoprostol or to other prostaglandins
- Confirmed or suspected ectopic pregnancy
- Signs of sepsis or active pelvic inflammatory disease
  - Women with sepsis may need postabortion care but their care should be managed if possible in an acute-level facility with ability to perform blood and cervical cultures and administer IV antibiotics if possible.
- Hemodynamic instability or shock
  - Women who are hemodynamically unstable need uterine evacuation as soon as their condition permits, with supportive care such as fluid replacement and/or blood transfusion.

**Precautions**

Women with the following conditions can use misoprostol, but they may require additional treatment and further care. Whether to administer misoprostol to women with these conditions will depend on the available options for safe postabortion care, referrals, and clinical judgment.

- IUD in place — remove before beginning the regimen
- Hemorrhagic disorder or concurrent anticoagulant therapy
  - In general, it may be safer for women with hemorrhagic disorder or who are taking anticoagulants to receive care in a health facility where they can be observed and monitored; vacuum aspiration (if available) may be the safer treatment choice.
- Severe anemia
- Uterine size larger than 12 weeks LMP
  - Uterine size larger than 12 weeks LMP may be due to presence of fibroids and, in this case, the woman would still be eligible for misoprostol for postabortion care.

---

4 This does not include infections limited to the vagina, such as yeast infections or bacterial vaginosis.
Women who are breastfeeding may take misoprostol. There is no evidence to suggest that misoprostol is harmful to infants, though it enters breast milk soon after taken. Misoprostol is undetectable in breast milk 4-5 hours after ingestion, so the woman can breastfeed, take misoprostol, and wait 4-5 hours for the next feed (Abdel-Aleem et al. 2003, Tang et al. 2007, Vogel et al. 2004).

E. Clinical assessment

It is important to note that diagnosis of incomplete abortion can be done with a targeted medical and obstetric history, symptoms and physical and pelvic exam. Pregnancy testing and ultrasonography are not routinely needed to diagnose incomplete abortion (Bique et al. 2007, Dabash et al. 2010, Ngoc et al. 2005, Shwekerela et al. 2007, Weeks et al. 2005).

The first step is to evaluate whether the woman is in a state of emergency or whether her condition is stable enough to provide misoprostol treatment for postabortion care. Clinical assessment is therefore divided into two sections: care of the woman who is stable and assessment of the woman who is unstable.

I. If the woman is in stable condition…

A. The woman is ambulatory and is not in acute distress.

B. Prepare the woman for what to expect — a series of questions followed by an exam. Clinicians should recognize the needs of special populations. For example, an adolescent may never have had a physical examination before and may be experiencing stress and concerns about the exam.

1. Targeted medical and obstetric history
   
   • Medical history
     › Is the woman taking any medicines now?
     › Is the woman allergic to any medicines or agents (i.e., iodine)?
     › Does the woman have a current acute medical illness, or does she have a chronic medical illness?
   
   • Obtain targeted medical history as it relates to misoprostol eligibility and precautions.
   
   • Get a brief obstetric and contraceptive history.
   
   • History of current pregnancy: LMP, when pregnancy symptoms began, when bleeding began, amount and duration of bleeding. Cramping or pain woman has experienced, severity of pain, nature of pain, whether intermittent (contractions) or constant.

2. Ancillary testing (if indicated and available)
   
   • Hemoglobin or hematocrit
   
   • Pregnancy testing is not routinely needed to diagnose incomplete abortion.
   
   • Ultrasonography is not routinely needed to diagnose incomplete abortion.

3. Physical exam
   
   • Vital signs: blood pressure, temperature, pulse
• General appearance (for example, indication of severe anemia, level of energy and alertness, is the woman able to walk into the exam room unaided or is she doubled over in pain, does she appear in general good health or does she appear very fatigued and pale).

• Pelvic exam
  › Uterine size, tenderness
  › Cervical motion tenderness
  › Adnexal mass suggestive of ectopic pregnancy
  › Speculum exam: cervical os open or closed, POC protruding from external os, purulent discharge from os, color and amount of blood in vaginal vault
  › Signs of pelvic infection (foul-smelling discharge, abdominal tenderness)

4. Treatment

• Discuss treatment options: misoprostol, manual vacuum aspiration (MVA), expectant management, or other. Medical eligibility, women’s preferences, and local circumstances (such as transport conditions and an assessment of women’s ability to manage the medical versus surgical options) should be considered in choosing the treatment method.

• Provide treatment.

• Describe to woman when she should come for follow-up and explain the warning signs of treatment complications (see F3: Warning signs).

• Women may take misoprostol in the clinic or at home. It is not necessary to observe women in the clinic following misoprostol administration, unless facility space permits and this is the woman’s preference.

• When using misoprostol to treat incomplete abortion, infection rates are very low (Shwekerela et al. 2007, Trinder et al. 2006, Weeks et al. 2005). Antibiotics should be used if history and physical exam are suggestive of infection or risk of infection (Blum et al. 2007).

II. If the woman is in emergency/unstable condition
(including if the woman appears syncopal, is short of breath, is in extreme pain, or is experiencing frank, profuse hemorrhage)...

1. Rapid initial assessment for shock

• Fast, weak pulse (rate ≥ 110 per minute)

• Low blood pressure (diastolic <60)

• Pallor (extremely pale, pallor of palms or around the mouth)

• Sweatiness

• Rapid breathing (respiration ≥30 per minute)

• Anxiousness, confusion or unconsciousness
• Frank, profuse hemorrhage

2. If woman is in shock or clinically unstable, determine the etiology of the condition and treat or refer accordingly

• If woman is conscious or a family member is present, find out:
  › If woman is on current medications
  › If woman has a serious health condition
  › If woman has known allergies

• Proceed immediately to stabilize the woman:
  › IV fluid volume or, after cross-match, whole blood replacement with large-bore IV catheter
  › Oxygen by mask if available

• If sepsis is suspected, blood and cervical cultures if possible

• Broad-spectrum IV antibiotics if indicated

• Uterine evacuation ASAP (as soon as possible) if indicated

• Determine underlying etiology of shock (for example, a ruptured ectopic pregnancy would require emergency surgery).

• If woman will be transported, she may need stabilization and volume replacement with IV fluids before/during transport.
  › Notify referral facility that woman is being transported and give report on her diagnosis and condition.

F. Treatment effects, side effects and complications

Most women will experience treatment effects after taking misoprostol. There are also possible side effects that a minority of women may experience. In a small number of cases, a woman may experience complications that will require her to seek immediate help from a clinician. Women should be counseled on what to expect after taking misoprostol and clinicians should ensure that women understand the warning signs that are indicative of a complication and require immediate assessment. For more information, see Tool 5G: Managing expected effects, side effects and complications.

1. Treatment effects

Expected effects of misoprostol for treatment of incomplete abortion include cramping, bleeding and expulsion of products of conception (POC). Generally, symptoms may occur within the first few hours after the medication is taken. Expulsion occurs over several hours to several weeks; bleeding will most likely be heavy for about three to four days, followed by light bleeding or spotting for several weeks (Blum et al. 2007). A recent study in Egypt, which compared vaginal bleeding after misoprostol and MVA treatment, concluded that the likelihood of a clinically significant decrease in hemoglobin (at least 2 g/dL) following either treatment was extremely low (less than 1 percent) (Dabash et al. 2010).
Management of treatment effects

Pain

Uterine contractions, which the woman experiences as cramping, are necessary to expel the products of conception and residual tissue. Ibuprofen or other non-steroidal anti-inflammatory drugs (NSAIDs) should be provided around the time of misoprostol administration or shortly thereafter (for example, ibuprofen 400-600mg orally every six hours). Good counseling and emotional support may also alleviate anxiety and reduce perceptions of pain.

Bleeding

Amount and duration of bleeding will vary from woman to woman, ranging from bleeding lighter than a menstrual period to bleeding much heavier than a menstrual period. Passage of clots and/or tissue is expected. In one randomized clinical trial of 300 women receiving misoprostol for postabortion care treatment, 24 percent of women using oral misoprostol and 26 percent of women using sublingual misoprostol experienced heavy bleeding in the two hours after taking misoprostol (Diop et al. 2009). Women should be prepared with full-thickness sanitary pads or similar cloths used locally. Provide information about the normal range of bleeding and warning signs that should prompt the woman to call her clinician or seek urgent medical care.

2. Possible side effects

Clinicians should discuss the side effects women may experience after taking misoprostol, including: chills/fever, nausea/vomiting, and diarrhea. Side effects are usually mild and self-limited, lasting less than 24 hours (Clark et al. 2007). Prolonged or serious side effects with misoprostol treatment are rare (Blum et al. 2007, Gemzell-Danielsson et al. 2007).

Management of side effects

All women should be counseled that chills/fever, nausea/vomiting and diarrhea are possible side effects of misoprostol treatment. Symptomatic treatment (such as administration of an antiemetic) is not routinely necessary, but may be helpful in select cases (for example, in a woman who is already vomiting or who has prior experience with misoprostol causing vomiting). If needed, antipyretics can be provided for the treatment of chills/fever. An example is ibuprofen 400-800mg every six hours.

3. Warning signs

Most women will not experience serious complications as a result of taking misoprostol for the treatment of incomplete abortion. However, women should be counseled on the warning signs that would indicate that they have a complication. If women experience one of the listed warning signs, they should immediately seek help from a health center clinician.

- Heavy bleeding
  - Soaking two full-thickness sanitary pads per hour for two consecutive hours
  - Heavy bleeding that occurs after bleeding had slowed down or stopped
  - Feeling light-headed or dizzy as bleeding continues
- Fever which lasts more than a day or starts any day after the day misoprostol is taken
• Severe pain, even on the day of misoprostol, that does not get better with medication, rest, or a heating pad

•Feels very sick

Management of heavy bleeding

Uterine evacuation (vacuum aspiration) is necessary if there are retained products of conception and heavy bleeding. Hemorrhagic disorders should be treated accordingly if they are the cause. Anemia resulting from heavy bleeding requiring treatment is rare (Dabash et al. 2010), but anemia can coexist as a condition in many reproductive age women. In those cases, anemia should be treated as necessary in addition to the vacuum aspiration for acute bleeding.

If persistent bleeding or intermittent mild (not severe) cramping does not improve by the time of the follow-up visit, a repeat dose of misoprostol or vacuum aspiration should be considered. If the woman is treated with a repeat dose of misoprostol, it is advisable to re-evaluate the woman again in one to two weeks. (See H: Follow-up).

If bleeding is profuse or prolonged and heavy, the woman should have vacuum aspiration.

If bleeding has been hemorrhagic or profuse/prolonged, blood transfusion may be necessary in rare cases to restore hemodynamic stability.

Management of infection

Signs of infection include:

• Fever that lasts more than a day or starts any day after the day the woman takes misoprostol

• Persistent abdominal pain

• Foul-smelling or purulent vaginal discharge

Where infection is confirmed, appropriate treatment with antibiotics should be given; in serious cases, hospitalization and IV antibiotics should be considered.

Management of constant cramping and pain

Persistent, unrelieved cramping or severe pain warrants evaluation prior to the follow-up visit (see F3: Warning signs).

Constant cramping and pain can result from treatment failure or to other complications, such as infection, unrecognized ectopic pregnancy, unrecognized tears, foreign bodies as a result of unsafe abortion practices, or some other health problem. Women should be reassessed carefully, and treated based on the root cause of the problem, along with symptomatic management of pain.

When treating incomplete abortion, clinicians may face complicated cases due to unsafe abortion practices to which women were exposed before they sought treatment of incomplete abortion. These could include uterine perforation, cervical tears, foreign objects in the vagina, infection or sepsis, or even shock due to excessive blood loss.

It is important to note that side effects and possible complications from surgical treatment of incomplete abortion may be different from those of medical management. Complications resulting from surgical treatment can include uterine perforation or infection caused by unhygienic surgical procedures.
G. Postabortion contraceptive counseling

Contraceptive counseling should be a routine part of postabortion care. Clinicians should provide information on the rapid return to fertility and offer appropriate contraceptive counseling and a method of the woman’s choice.

• Most contraceptive methods should be provided as soon as possible — usually the same day as misoprostol. Highly effective contraception, such as injectables, contraceptive implants and oral contraceptives can be administered on the same day that misoprostol is given.

• The intrauterine device (IUD) may be inserted at follow-up if the misoprostol treatment was successful.

• If there will be more than a 10-day delay before a woman can start a chosen method, another method, such as condoms, should be provided in the interim.

• Emergency contraception can also be provided to women to take in the event of unprotected intercourse.

• Women should be counseled to delay intercourse until contraception is in place if they want to prevent another pregnancy.

H. Follow-up

A follow-up visit should be scheduled one to two weeks following misoprostol administration if feasible; depending on the local circumstances, clinicians also may suggest alternatives to follow-up.

Follow-up visits should cover the following:

**Treatment outcome:** To determine if treatment was successful, the clinician should ask the woman about her experience and then conduct a physical exam. *Treatment success is defined as complete uterine evacuation and resolution of all symptoms.*

• **History** suggestive of successful treatment:
  - The woman experienced bleeding. (Bleeding can range from lighter than a normal menstrual period to much heavier than a menstrual period, with large clots.) The woman also experienced cramping and passage of clots or tissue, but bleeding and cramping have now subsided or are minimal.
  - Pregnancy symptoms have lessened or disappeared and the woman does not feel pregnant.

• **Physical exam** suggestive of successful treatment:
  - Minimal or absent bleeding
Normal uterine size (small, firm)

Nontender uterus and adnexae and no cervical motion tenderness

Closed cervical os

**Continued incomplete abortion:** If the evacuation process is not yet finished at the follow-up visit and the woman is clinically stable, she may be offered close observation with expectant management and be re-evaluated in one to two weeks. Alternatively, a repeat dose of misoprostol may be offered (Blum et al. 2007). If the woman is treated with a repeat dose of misoprostol, it is advisable to re-evaluate her in one to two weeks. In the event of infection or clinically significant bleeding, completion with vacuum aspiration should be considered.

**Contraception:** If the woman wishes to avoid a subsequent pregnancy, ensure that she is comfortable with her contraceptive method, or offer counseling and a method if these have not yet been provided.

**Reproductive health:** Link the woman with other reproductive health services as needed, such as cervical cancer screening, HIV testing or care, referral to a fertility clinic or fertility services, care for sexual violence, and others.
References


This toolkit is promoted by the following organizations:

Population Council
Ipas
Venture Strategies Innovations
PLANNED PARENTHOOD
MARIE STOPES INTERNATIONAL
Venture Strategies for Health and Development
UNFPA
IPPF
IntraHealth
EngenderHealth
Pathfinder International
Bixby Center for Population, Health & Sustainability
IMPROVING WOMEN'S HEALTH IN KENYA
IntraHealth
Because Health Workers Save Lives.
Qualicare Health Services
Jhpiego
an affiliate of Johns Hopkins University
Postabortion Care PAC Consortium
IDEAS
Innovative Development Expertise & Advisory Services, Inc.
FIGO
International Federation of Gynecology & Obstetrics
AMAN
Association for Mothers & Newborns
K-MET
Ethiopian Midwives Association
NCMH
National Committee for Maternal & Neonatal Health

If your organization is interested in being added as a promoting agency to future printing and online versions of this toolkit, please contact misoforpac@ipas.org.